 
I8H- MC-BDCM Clinical Protocol  
 
 A Phase 2, Randomized, Open- Label Trial to Evaluate the  Safety and Efficacy of LY3209590 in 
Study Participants with Type 2 Diabetes Mellitus Previously Treated with  Basal Insulin  
 
[STUDY_ID_REMOVED] 
 
Date: 31-Aug-2018 
 
 
I8H-MC-BDCM Clinical Protocol Page 1
LY3209590Protocol I8H-MC-BDCM
A Phase 2, Randomized, Open -Label Trial to Evaluate the 
Safety  and Efficacy  of LY3209590 in Study  Participant s 
with Ty pe 2 Diabetes Mellitus Previously  Treated with 
Basal Insulin
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY3209590 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries .  
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, thi s document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Basal Insulin -Fc (LY3209590 )
Eli Lilly and Company
Indian apolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly on date provided below .
Approval Date: 31-Aug-2018 GMT
I8H-MC-BDCM Clinical Protocol Page 2
LY3209590Table of Contents
Section Page
Protocol  I8H-MC-BDCM A Phase 2, Rando mized, Open -Label Tri al to 
Evaluate the Safet y and Efficacy of LY3209590 in Study  Parti cipants 
with Type 2 Di abetes Mellitus Previously Treated with Basal Insulin .................................. 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 9
2. Schedule of Act ivities....................................................................................................... 12
3. Introduction ...................................................................................................................... 20
3.1. Study  Rati onale ............................................................................................................ 20
3.2. Background .................................................................................................................. 20
3.3. Benefit/Risk Assessment .............................................................................................. 21
4. Object ives and Endpo ints.................................................................................................. 22
5. Study  Design ..................................................................................................................... 24
5.1. Overall Design ............................................................................................................. 24
5.1.1. S tudy Visi ts.......................................................................................................... 25
5.2. Number of Participants .................................................................................................27
5.3. End of Study  Definit ion............................................................................................... 27
5.4. Scientific Rationale for Study  Design ........................................................................... 27
5.5. Justification for Dose ................................................................................................... 28
6. Study  Popul ation............................................................................................................... 29
6.1. Inclusio n Cri teria.......................................................................................................... 29
6.2. Exclusio n Cri teria........................................................................................................ 31
6.3. Lifest yle Restrict ions.................................................................................................... 33
6.4. Screen Failures ............................................................................................................. 33
7. Treat ments ........................................................................................................................ 34
7.1. Treatments Administered ............................................................................................. 34
7.1.1. Packaging and Labeling ....................................................................................... 34
7.2. Method of Treatment Assignment ................................................................................ 35
7.2.1. Selection and Timing o f Doses ............................................................................. 35
7.2.1.1. LY3209590 Algorithms .................................................................................. 35
7.2.1.2. Insulin Degludec ............................................................................................. 36
7.3. Blinding ....................................................................................................................... 37
7.4. Dosage Modification .................................................................................................... 37
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 37
7.6. Treatment Compliance .................................................................................................38
I8H-MC-BDCM Clinical Protocol Page 3
LY32095907.7. Concomitant Therapy ................................................................................................... 38
7.7.1. Antihyperglycemia Medicat ions........................................................................... 39
7.7.2. Concomitant Ant ihyperglycemia Medicat ion....................................................... 40
7.7.3. Medicat ions that Promote Weight Loss ................................................................ 40
7.7.4. Systemic Glucocorti coids..................................................................................... 41
7.7.5. Antihypertensive Medications .............................................................................. 41
7.7.6. Dyslipidemia Medicat ions.................................................................................... 41
7.8. Treatment After the End of the Study ........................................................................... 41
7.8.1. Treatment After Study  Com pletion....................................................................... 41
7.8.2. Speci al Treatm ent Consi derat ions........................................................................ 42
7.8.2.1. Standards of Medical Care .............................................................................. 42
7.8.2.2. Management of Increased Hypoglycemia Risk ............................................... 42
7.8.2.3. Management of Study  Parti cipants wi th Severe, 
Persi stent Hy perglycemia during the Treatment Period ................................... 43
7.8.2.4. Emergency  Situations..................................................................................... 43
8. Discontinua tion Cri teria .................................................................................................... 44
8.1. Discontinuati on from Study  Treatm ent......................................................................... 44
8.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 44
8.1.2. Temporary  Discont inuat ion from Study  Treatm ent............................................... 45
8.1.3. Discontinuati on of  Inadvertent ly Enrolled Study  Parti cipants ............................... 45
8.2. Discontinuati on from the Study .................................................................................... 45
8.3. Lost to Follow -Up........................................................................................................ 46
9. Study  Assessments and Procedures ................................................................................... 47
9.1. Efficacy Assessments ................................................................................................... 47
9.1.1. Primary Efficacy  Assessments ............................................................................. 47
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 47
9.1.3. Appropriateness of Assessments .......................................................................... 47
9.1.4. Body  Weight ........................................................................................................ 47
9.2. Adverse Events ............................................................................................................ 48
9.2.1. Serious Adverse Events ........................................................................................ 48
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 49
9.2.2. Adverse Events of Special Interest ....................................................................... 50
9.2.2.1. Hypoglycemia ................................................................................................ 50
9.2.2.2. Allergic/Hypersensit ivity Reactions ................................................................ 51
9.2.3. Adverse Event Monitoring with a Systemat ic Questionnaire ................................ 51
9.2.4. Com plaint Handling ............................................................................................. 51
9.2.4.1. Device Complaint Handling ............................................................................ 51
9.3. Treatment of Overdose ................................................................................................
.51
I8H-MC-BDCM Clinical Protocol Page 4
LY32095909.4. Safety........................................................................................................................... 51
9.4.1. Cardi ovascular Events .......................................................................................... 51
9.4.2. Electrocardiograms .............................................................................................. 52
9.4.3. Vital Signs ........................................................................................................... 52
9.4.4. Self-monitoring o f Blood Gl ucose Using CGM .................................................... 52
9.4.5. Continuous Glucose Monitoring ........................................................................... 53
9.4.6. Laboratory  Tests .................................................................................................. 54
9.4.7. Immunogenicit y Assessments .............................................................................. 54
9.4.8. Other Tests ........................................................................................................... 55
9.4.9. Safety Moni toring ................................................................................................ 55
9.4.9.1. Hepati c Safet y Moni toring .............................................................................. 55
9.5. Pharmacokinet ics......................................................................................................... 56
9.6. Pharmacodynamics ...................................................................................................... 56
9.7. Pharmacogeno mics ...................................................................................................... 56
9.7.1. Who le Blood Samples for Pharmacogenet ic Research .......................................... 56
9.8. Biomarkers ................................................................................................................... 57
9.9. Heal th Economics ........................................................................................................ 57
10. Statistical Considerations .................................................................................................. 58
10.1. Sample Si ze Determinat ion.......................................................................................... 58
10.2. Analysis Sets ................................................................................................................ 58
10.3. Statistical Analyses ...................................................................................................... 58
10.3.1. General Statist ical Considerat ions........................................................................ 58
10.3.2. Treatment Group Comparabilit y........................................................................... 59
10.3.2.1. Study  Parti cipant Disposit ion.......................................................................... 59
10.3.2.2. Study  Parti cipant Characterist ics..................................................................... 59
10.3.2.3. Concomitant Therapy ..................................................................................... 59
10.3.2.4. Treatment Compliance .................................................................................... 59
10.3.3. Efficacy Analyses ................................................................................................ 60
10.3.3.1. Primary Analyses ........................................................................................... 60
10.3.3.2. Secondary  Analyses ........................................................................................ 60
10.3.3.3. Exploratory  Analyses ..................................................................................... 61
10.3.4. Safety Analyses .................................................................................................... 61
10.3.4.1. Adverse Events ............................................................................................... 61
10.3.4.2. Vital Signs
...................................................................................................... 62
10.3.4.3. Hypoglycemia Episodes ................................................................................. 62
10.3.4.4. Laboratory  Measures ...................................................................................... 62
10.3.4.5. Electrocardiograms ......................................................................................... 63
10.3.4.6. Adverse Events of Special Interest .................................................................. 63
I8H-MC-BDCM Clinical Protocol Page 5
LY320959010.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 63
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 63
10.3.7. Other Analyses ..................................................................................................... 64
10.3.7.1. Health Economics ........................................................................................... 64
10.3.7.2. Subgroup Analyses ......................................................................................... 64
10.3.8. Interim Analyses .................................................................................................. 64
11. References ........................................................................................................................ 65
12. Appendices ....................................................................................................................... 66
I8H-MC-BDCM Clinical Protocol Page 6
LY3209590List of Tables
Table Page
Table BDCM.1. Schedule of Act ivities.................................................................................... 13
Table BDCM.2. Object ives and Endpo ints............................................................................... 22
Table BCDM.3. Treatment Regimens ...................................................................................... 34
Table BDCM.4. Criteria for Use of Concomitant Medica tions that may Interfere with 
Efficacy and Safet y Assessments in Study  BDCM ......................................... 39
Table BDCM.5 LY3209590 Loading Dose ............................................................................. 81
Table BDCM.6 LY3209590 Titration Algori thm.................................................................... 82
I8H-MC-BDCM Clinical Protocol Page 7
LY3209590List of Figures
Figure Page
Figure BDCM.1. Illustrati on of  study  design for Clinical Protocol I8H -MC-BDCM. ................ 10
Figure BDCM.2. Illustrati on of  study  design for Clinical Protocol I8H -MC-BDCM. ................ 24
I8H-MC-BDCM Clinical Protocol Page 8
LY3209590List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 67
Appendix 2. Clinical Laboratory  Tests ............................................................................... 70
Appendix 3. Study  Governance Considerat ions.................................................................. 72
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 77
Appendix 5. Methods of Contraception .............................................................................. 78
Appendix 6. New York Heart Associat ion Cardiac Disease Classificat ion......................... 79
Appendix 7. Dosing Guidance ........................................................................................... 80
I8H-MC-BDCM Clinical Protocol Page 9
LY32095901.Synopsis
Title of Study:
A Phase 2, Rando mized, Open -Label Trial to Evaluate the Safet y and Efficacy  of LY3209590 in 
Study Participant s with Type 2 Di abetes Mellitus Previously  Treated wi th Basal  Insulin
Rationale: 
LY3209590 i s along-acting insulin receptor agonist being developed for the treatm ent of ty pe 2 
diabetes m ellitus(T2DM). This Phase 2 study  of LY3209590 will evaluate the effects of 
LY3209590 on glycemic control using 2 different dose individualizat ion strategi es co mpared 
with insulin degludec in study  parti cipant s previously treated with basal insulin.
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To investigate the efficacy of LY 3209590 
arms instudy participant s with T2DMHbA1c change from baseline to Week 32
Secondary
Efficacy :
To investigate the efficacy of LY3209590 
compared with insulin degludec in study 
participant s with T2DMHbA1c change from baseline to Week 12 and 
32
Fasting glucose change from baseline to 
Weeks 12 and 32
Insulin dose change from baseline to week 12 
and 32 
Safety:
To investigate the safety of LY3209590
compared with insulin degludec instudy 
participant s with T2DMIncidence and Rate of nocturnal and 
documented symptomatic hypoglycemia 
events during the treatment period
Incidence of treatment -emergent serious 
adverse events
Body weight change from baseline at Weeks 
12 and 32
Pharmacokinetics :
To characterize the PK of LY3209590 in 
study participant s with T2DMLY3209590 population -based parameters, 
such as, AUC within dosing interval at Weeks 
12 and 32
Abbreviations:  AUC =area under the curve; HbA1c = hemoglobin A1c; PK =pharmacokinetics; T2DM =type 2 
diabetes mellitus
I8H-MC-BDCM Clinical Protocol Page 10
LY3209590Summary of Study Design:   
Study  I8H-MC-BDC M(BDCM) is a multicenter, ran domized, open -label, comparator -controlled 
Phase 2 study  with 3 study  periods:  2-week screening, 32-week treatment period, and 5 -week 
safet y follow-up peri od. The study  is designed to evaluate the efficacy  and safet y of LY3209590 
compared toinsulin degludec in study  partici pants with T2DM .The primary  endpoint will be 
hemoglo bin A1c (HbA1c ) change fro m baseline to 32weeks.
Treatment Arms and Duration:   
Study  parti cipant s will be rando mized in a 1:1:1 ratio to one of two dosing algorithms o f 
LY3209590 or insulin degludec.
Figure BDCM .
1illustrates the study design.
Figure BDCM .1. Illustration of study design for Clinical Protocol I8H-MC-BDCM .
Number of Study P articipant s
:
A total o f 536 study  parti cipant s with T2DM previously treated with basal insulin will be 
screened . Approximately 375 study  participant s will be rando mized in a 1:1:1 ratio to 

I8H-MC-BDCM Clinical Protocol Page 11
LY3209590LY3209590 in one of two dosing algorithms (125 study  participant s in each treatment arm) or 
insulin degludec (1 25 study  parti cipants).
To ensure the safet y of the screened study  parti cipant s,a continuous glucose monitoring system 
will be used during the course of exposure to the investigational product ,to alert study  
participants in case of expected or evident hy poglycemia.
Statistical Analysis:   
Efficacy Analysis:   
The primary  efficacy  outcome i s HbA1c change from baseline to Week 32for the LY3209590 
arms.  
Safety Analysis:   
The full analysis set ( FAS), which includes all data, regardless of res cue medicat ion use or early 
stop of study  medicat ion,will be used for safet y analyses.  Both the overall and the pairwise 
comparisons of each LY3209590 armversus insulin degludec will be reported for these safet y 
analyses.
Safety measures include liver bio markers alanine aminotransferase (ALT), hy poglycemia, vital 
signs(blood pressure [ BP]and pulse rate) , body  weight, treatm ent-emergent adverse events 
(TEAEs including serious adverse events [SAEs ]and adverse events of special interest [AESI] ), 
laboratory  measures (including anti -LY3209590 antibodies), and electrocardi ograms(ECGs).
Summary  statistics will be presented by  treatm ent for the safet y measures.
The summary statistics for continuous variables will be sample size, mean, standard deviat ion
(SD) , median, minimum, and maximum.
The summary statistics for categorical variables will be sample size, frequency, and percentage.
Exposure to each therapy  during the treatm ent period of the study  will be calculated for each 
study  participant and summarized by treatm ent group.
Addit ional pharm acokinet ics (PK)/pharmacodynamic (PD)analys es, such as concentration -
response for glucose and safety  laboratory data, may  be performed upon review of the data.
I8H-MC-BDCM Clinical Protocol Page 12
LY32095902.Schedule of A ctivities
I8H-MC-BDCM Clinical Protocol Page 13
LY3209590Table BDCM .1. Schedule of A ctivities
Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Informed consent X
Inclusion and 
exclusion criteriaX
Randomization Xa
Study  
participants may 
resume  pre -
study  insulin X
Clinical 
Assessments
Height X
Body weightaX X X X X X X X X X X X XSee Section 
9.1.4
Blood pressure 
and pulse ratea X X X X X X X X X X X X XSee Section
9.4.3
Demography X
Medical history 
(includes 
substance usagea
and history of 
CV disease )XSubstances: 
(drugs, 
alcohol, 
tobacco and 
caffeine )
I8H-MC-BDCM Clinical Protocol Page 14
LY3209590Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Pre-existing 
conditionsX X
Concomitant 
medication 
reviewX X X X X X X X X X X X
Full physical 
examinationX X X X X X
12-lead ECG X XdXdXdXdXdXdXdXdXdXdFor screening 
visit, collect a 
single, local 
ECG
Hypoglycemia 
eventsX X X X X X X X X X X X X X X X X X X X X X X X X
AE/SAE review X X X X X X X X X X X X X X X X X X X X X X XWill include 
injection site 
inspections
Laboratory 
Assessments
LY3209590 PK XeX X X X X X X X X X X  X X X XSee Section
9.5
Fasting X X X X X X X X X X X X
Serum 
pregnancy test 
(WCBP only)aXSee Section
5.1
Central lab
I8H-MC-BDCM Clinical Protocol Page 15
LY3209590Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Urine pregnancy 
test (WCBP 
only)X X X X X Local lab
Urinalysis X X X X X X
Chemistry panelaX X X X X X X X X X X XVisit 2: 
glucose, AST, 
ALT, GGT 
only
Pancreatic 
AmylaseX
Lipase X
Hepatitis B X
HbA1c X X X X X X X X X
Hematology X X X X X X X X X X X
FSH XFemale study 
participant s 
only
eGFR X X X X
HDL, LDL X X X X X X X X
Free fatty acid, 
triglycerides X X X X X X X X X X XCollected in 
fasting state
C-peptide X X X X X X X X XCollected in 
fasting state
LY3209590 anti -
drug antibodiesa X X X X X X X X XSee Section
9.4.7
I8H-MC-BDCM Clinical Protocol Page 16
LY3209590Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Pharmaco -
genetic sampleX
Biomarker 
stored sample 
(plasma/
serum)X X X X X X X X X 
Ancillary 
Supplies/
Diaries/
Investigational 
Product
Study  participant
training/
educationaXIncludes 
diabetes 
counseling, 
hypoglycemia 
(9.2.2.1 ), 
FPG profiles, 
diary 
completion, 
CGM sensor 
replacement
Study  participant
CGM TrainingX
I8H-MC-BDCM Clinical Protocol Page 17
LY3209590Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
CGM Sensor 
InsertionXSensor 
inserted and 
system started 
by study 
participant
under site 
person al 
supervision
Distribute CGM 
sensorf X X X X X X X X X X X X X X X X X X X
CGM data 
downloadX X X X X X X X X X X X X X X X X X X X X
Dispense 
supplies and 
diaryX X X X X X X X X X
IWRS X X X X X X X X X X X X X X X X X X X X X X X X X
Record diary and 
CGM data 
(including FPGg, 
hypoglycemia )X X X X X X X X X X X X X X X X X X X X X X X
Review diary 
and CGM data 
(including FPGg, 
hypoglycemia )X X X X X X X X X X X X X X X X X X X X X X
I8H-MC-BDCM Clinical Protocol Page 18
LY3209590Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
Record recent 
study  drug 
dose/dose 
adjustmentX X X X X X X X X X X X X X X X X X X X X X
Dispense IP X X X X X X X X X X X X X X X
Study  personnel 
administer IP at 
siteX X X X X X X X X
Train study 
participant
in IP 
administrationX X X X X X X X
Study  participant
or study 
personnel 
administer at 
siteaX X X X X XWeeks
13 - 31
(except Week 
18): study 
participant s 
may self-
administer 
injection at 
home or have 
injection done 
at site
I8H-MC-BDCM Clinical Protocol Page 19
LY3209590Procedure Screening
and
Lead -inTreatment Period Follow -up ET Notes a
eCRF Visit 
Number1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16b17 18b19b20 21 22b801c802c803c
Weeks -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 15 18 21 24 28 32 33 37
Visit window, 
days±7 ±3 ±2 ±2 ±3 ±2 ±2 ±3 ±2 ±2 ±2 ±2 ±2 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3
LY3209590 
accountability 
(collect used and 
unused IP)X X X X X
Insulin degludec 
accountability 
(collect unused 
pens)X X X X X X X X X X X X X X X X X
Abbreviations:  AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BG = blood glucose; CGM = continuous glucose 
monitoring; CV = cardiovascular; eCRF = electronic case report form; eGFR = estimated glomerular filtration rate; ECG = electrocardiogram; ET = early  
termination; FPG = fasting plasma glucose; FSH = follicle stimulating hormone; GGT = gamma -glutamy l transferase; HbA1c = glycated hemoglobin ;
HDL = high density lipoprotein; IP = investigational product; IWRS = interactive web -response sy stem; LDL = low density lipoprotein; LY = LY3209590 ;
PK = pharmacokinetics; SAE = serious adverse event; SMBG = self-monito ring of blood glucose; WCBP = women of child bearing potential.
aIndicates that a relevant note is included in the last column.
bPhone visit
cStudy activities at Visits 802 and 803 are identical to Week 32 (Visit 21) and Visit 801, respectively.
dA triplicate, central ECG will be performed prior to the time of each PK sampling. These ECGs will be performed in a fasting state. 
eCollect 2 PK samples: one predose and one approximately 2 hours postdose or as late as possible just prior to departure from the site.
fStudy participants will replace CGM sensor according to system label at home and will be trained for this procedure at Visit 3. At each visit study participants
will be supplied with the necessary sensors for the respective int erval.
gOccurs t he week prior to the scheduled dose adjustment check .FPG should be collected daily for 
 prior to dose adjustment for calculating average 
FPG.
CCI
I8H-MC-BDCM Clinical Protocol Page 20
LY32095903.Introduction
3.1. Study Rationale
LY3209590 is a long-acting insulin receptor agonist with a half -life enabling weekly dosing 
developed for the treatm ent of  type 2 di abetes m ellitus(T2DM ).  This Phase 2 study  of 
LY3209590 will:
Evaluate the effects of LY3209590 on glycemic control using 2 different dose 
individualizat ion strategies co mpared with insulin degludec in study  parti cipant s 
previously treated with basal insulin .
3.2. Background
LY3209590 was designed as a novel , once -weekly ,long-acting insulin receptor agonist that is 
intended for the treatm ent of hyperglycemia in study  parti cipant s with T2DM.   A once weekly 
insulin receptor agoni sthas the potential to increase willingness to initiate and compliance with 
an insulin therapy i n study  parti cipant s with T2DM. In real life only about a quarter of these 
study p articipant s reach the target HbA1c of 7% (Blonde L et al . 2014 )and a once weekly 
insulin receptor agoni stcould hel p to increase this number. The potential downside o f such a 
long act ing insulin receptor agoni stcould be a higher ri sk for hypoglycemic events or a longer 
durati on of  such events. The recent ly launched l ong acting insulin degludec has nevertheless 
shown a reduced potential to induce hypoglycemia as compare d to i nsulin glargine while its 
half-lifeis twice as long as that of insulin glargine (Heise et al . 2012 ).  The current phase 2 study  
will therefore evaluate the safet y and efficacy of LY3209590 as com pared to insulin degludec 
while very  closely m onitorin g glycemic profiles using continuous glucose monitoring.
Data from  the single -ascending dose (SAD) study  dem onstrated cl ear evi dence of glucose 
lowering in study  parti cipant s with T2DM at single doses ranging from 
. The 
pharmacokinet ics (PK)of LY3209590 fo llowing single doses demonstrated prolonged time -
action profile to support once -weekly  administration.  LY3209590 reached maximum 
concentration approximately  after dos ing, followed by  amean eliminat ion half-life o f 
approximately  in study  participant s with T2DM. With a 
long eliminat ion half-life, following a weekly  fixed -dose regimen , PK steady -state is reached in 
approximately  and resul tsin approximately r concentration than after 
single dose . However, using a loading dose strategy  that is , 
 on PK modeling .PK fo llowing a
single loading dose  during t he first week was demonstrated to be 
comparable to concentration profile at Week  based on 
preliminary data in the mult iple ascending dose (MAD) study .  No clinically  significant 
persistence in hypoglycemia was observed in the study . Besides the known risk of
hypoglycemia ,no relevant safet y signals have been observed in the Phase 1 studies. Addit ional 
inform ation about LY3209590 can be found in the Invest igator’s Brochure.
The toxicit y profile of LY3209590 has been characterized in 6 -week and 6 -monthrepeat -dose 
toxicology studi esin rat sand dog s,and reproductive toxico logy studi es in rats and rabbits .  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I8H-MC-BDCM Clinical Protocol Page 21
LY3209590These studies demonstrated a familiar spectrum of effects ty pically  associated wi th changes 
secondary  to hy poglycemia and/or hy perinsulinemia result ing from repeat dosing of exogenous 
insulin in normoglycemic test sy stem s.  All  findings were consi dered to be target -related with no 
evidence of off- target effects in any  of the param eters assessed. Addit ional informat ion about 
LY3209590 can be found in the Investi gator’s Brochure.
3.3. Benefit/Risk Assessment
The data from the SAD study  and the ongoing MAD study  (Studi es BDCA and BDCB) have 
shown that LY3209590 was well tolerated and the adverse drug reactions are in line with those 
reported for long acting insulins.
Potenti al risks associated wi th LY3209590, derived from the known risks of long act ing insulins 
are hypoglycemia, hypersensit ivity react ions (localized allergy and/or sy stemic allergy ), 
undesirable effects at the inject ion site (inject ion-site reacti ons and lipody strophy ), and 
peripheral  edema. An addit ional risk based on preclinical data could be an elevat ion of liver 
aminotransferases. To date ,this has not been observ ed in study  parti cipant s or healt hy 
volunteers exposed to LY3209590 for up to 6 weeks .
More informat ion about the known and expected benefits, risks, S erious Adverse Events(SAE)
and reasonably ant icipated AEs of LY3209590 are to be found in the Invest igator’s Brochure.
I8H-MC-BDCM Clinical Protocol Page 22
LY32095904.Objectives and Endpoints
Table BDCM .2shows the object ives and endpoints of the study .
Table BDCM .2. Objectives and Endpoints
Objectives Endpoints
Primary
To investigate the efficacy of LY 3209590 arms 
instudy participant s with T2DMHbA1c change from baseline to Week 32
Secondary
Efficacy
To investigate the efficacy of LY3209590 
compared with insulin degludec in study 
participant s with T2DM.HbA1c change from baseline to Week 12 and 
32
Fasting glucose change from baseline to Weeks 
12 and 32
Insulin dose change from baseline to week 12 
and 32
Safety
To investigate the safety of LY3209590
compared with insulin degludec in study 
participant s with T2DM.Incidence and rate of hypoglycemia 
Incidence and rate of nocturnal hypoglycemia
Incidence and rate of severe hypoglycemia
Incidence of treatment -emergent serious AEs
Body weight change from baseline at Weeks 12 
and 32
Pharmacokinetics 
To characterize the PK of LY3209590 in study 
participant s with T2DMLY3209590 population -based parameters, such 
as, AUC within dosing interva lat Weeks 12 
and 32
Exploratory
To investigate the safety and tolerability of 
LY3209590 compared with insulin degludec in
study participant s with T2DM.Treatment -emergent AEs
Discontinuation of IP due to AEs
Clinical laboratory results
Systematic assessment of injection site 
reactions
Insulin dose during follow up period
Incidence and rate of hypoglycemia during 
treatment and follow -up period
Incidence and rate of daytime hypoglycemia
Liver aminotransferase change from baseline to 
Weeks 12 and 32
To explore quality of glycemic control 
compared with insulin degludec using CGMGlucose time in target range, time in 
hyperglycemia, time in hypoglycemia
Duration and recurrence of hypoglycemic 
events 
To establish the relationships between 
dose/ exposure and key safety and efficacy 
measures for LY3209590 
To evaluate dose/ exposure and key safety and 
efficacy measures following different dosing LY3209590 exposure -response relationships 
with fasting glucose, SMBG, HbA1c, 
hypoglycemia, body weight, b lood pressure, 
pulse rate, and QTc , 
Relationship of LY3209590 dose to efficacy 
I8H-MC-BDCM Clinical Protocol Page 23
LY3209590Objectives Endpoints
regimens (HbA1c, fasting glucose) and safety 
(hypoglycemia) .
To characterize the effects of LY3209590 on 
exploratory PD biomarkers
To explore the development of LY3 209590 
ADAsPlasma lipids (cholesterol, LDL, HDL, 
triglycerides)
Biomarkers of lipolysis (FFA)
The frequency of antibody formation to 
LY3209590 will be determined.  
Abbreviation s:  ADA =antidrug antibodies; AE=adverse events; AUC = area under the curve; CGM = continued 
glucose monitoring ;FFA =free fatty acids; HbA1c = hemoglobin A1c; HDL =high density lipoprotein;
IP = investigational product; LDL =low density lipoprotein; PD =pharmacodynamics; PK =pharmacokinetics; 
QTc =corrected QT interval; SMBG =self-monito ringof blood glucose; T2DM =type 2 diabetes me llitus.
I8H-MC-BDCM Clinical Protocol Page 24
LY32095905.Study  Design
5.1. Overall Design
Study  I8H-MC-BDC M (BDC M)is a multicenter, ran domized, open -label, com parator -controlled 
Phase 2 study  with 3 study  periods. A total of 536study  participant s with T2DM ,previously 
treated with 
basal insulin will be screened .Approximately  375study  partici pants will be 
rando mized in a 1:1:1 ratioto LY3209590 in one of two dosing algorithms (Appendix 7 )or 
insulin degludec (modified Ri ddle algori thm, Section 7.2.1.2). The study  is designed to evaluate 
the efficacy and safet y of LY3209590 compared wit h insulin deglude c.
The study  will consist of 3 peri ods:  2-week screening, 32-week treatment period, and 5 -week 
safet y follow-up peri od.
Study  governance considerations are described in detail in Appendix 3 .
Figure BDCM .2illustrates the study design.
Figure BDCM .2. Illustration of study design for Clinical Protocol I8H-MC-BDCM .

I8H-MC-BDCM Clinical Protocol Page 25
LY32095905.1.1. Study Visits
Study Period 1: Screening and Lead -in
The purpose of procedures at screening is to establish eligibilit y for incl usion in the study  (see 
Secti ons 6.1and 6.2  During this period, study  participant s will be trained on disease monitoring 
and disease management procedures, study  diari es and study  procedures. Visit -specific subject 
diaries will  be dispensed at Vi sit 2 and as specified in the Schedule of Activit ies (Secti on 2)for 
future vi sits.
During the l ead-in period, study  parti cipant s should conti nue the sam e formulation and dose of 
their previ ously used insulin therapy, as well  as allowable oral antidiabet ic medicat ions (OAMs -
sulfo nylureas [SU]and meglit inides, dipept idyl pepti dase-
4 [DPP-IV]inhibitors, sodium-glucose 
cotransporter 2 [SGLT -2]inhibitors, biguanides, and alpha -glucosidase inhibitors ) in order t o 
allow reliable assessment of hemoglo bin A1c ( HbA1c )at randomizat ion (see Section 7.7.2 ).
Continuing Glucose Monitoring :  
A standard system will be used for continuing glucose monitoring (CGM )in an unblinded mode. 
The study  parti cipant s will wear this device beginning on Day 0 at randomization ,as shown in 
the Schedule of Act ivities(Secti on 2). In addit ion, all study  partici pants will be allowed to use 
their blood gl ucose m eters for addit ional blood glucose testing or for calibrat ion of the CGM 
system  if deemed necessary ,or for taking self -monitored pl asma gl ucose (SMPG) measurements 
during the outpatient period.
At the rando mizat ionvisit (Vi sit 3), study participant s will be trained on the use of the CGM 
device, CGM sensor replacement, interpretati on of CGM ba sed blood glucose values and alarms, 
and the requirements for CGM.  For the first CGM sessio n, study  partici pants meet ing all 
study -entry  criteria will have the CGM sensor inserted as part of the Visit 3 activit ies.
Study Period 2: Treatment Period
Random ization ( Week 0 [ Visit 3 ])
Study  parti cipant s who conti nue to be eligible for the study  will be rando mized to 1 of the 
treatm ent arm s.  All  measures to be performed at Visit 3 (see Schedule of Act ivities, Section 2)
shoul d be done pri or to inject ion of the study  partici pant’s assigned invest igational product (IP) 
to ensure that appropriate baseline measurements are obtained. Urine and serum  pregnancy tests
will be done before IP administration.  The study  parti cipant will begin IP ,if the urine pregnancy 
test i s negat ive. If the result of the serum pregnancy test is positive, the study  parti cipant will be 
discontinued fro m the study  (see Secti on8.2)
.
Study  personnel will inject the first dose of IP at the study  site.  The PK sample sand ECGs at 
rando mizat ion must be collected as described in the Schedule of Act ivities (Secti on 2).
Following rando mizat ion, study  parti cipant s will participate in a 32-week treatm ent peri od. 
During Weeks 1to 8, site personnel will administer IP, and study  parti cipant s will receive 
education and training on how to self-administer IP. The training should include informat ion on 
reconstitution of IP, appropriate inject ion site locatio ns, inject ion technique, and the signs and 
I8H-MC-BDCM Clinical Protocol Page 26
LY3209590symptoms of local adverse reactions, should that occur. During Weeks 9 to 12, IP will be 
reconstituted and administered at the site by  the study  parti cipant , under supervisio n of trained
site personnel to assure that the study  parti cipantis capable of self -administration .  During 
Weeks 13to 31IP will be self -administered by the study  parti cipant at home, or optionally can 
be administered once weekly  by si te personnel . Inform ation on self -inject ioncan be reviewed as 
necessary  through out the study .
LY3209590 will be administered as one of twodose individualizat ion algorithms ( Appendix 7 ).
Insulin degludec will be self-administered daily  by study  parti cipant s after a training and first 
administration under site personnel  supervisi on on Day  1according to a modified Riddle 
algorithm (Secti on 7.2.1.2 ).
General con siderations
Study  procedures will be per formed as listed in the Schedule of Activit ies (Secti on 2).
In order to allow timely  sampling for PK assessments, visits for collection of the samples will be 
scheduled within the required time windows provided in the Schedule of Act ivities (Secti on 2).
Study  parti cipant s will cont inue to use concomitant OAMs throughout the treatment period:  
discontinuat ion or changes to dose are not permitted, except in situat ions where dose adjust ment 
or com plete di scont inuation is required per country
-specific label or when allowed per study  
protocol  (for further details see Section 7.7.2 ).
Study  parti cipant s will b e instructed to document fasting plasma glucose (F PG) each day by 
using the values displayed on their CGM device after wakening or using a finger -stick glucose 
measurement .  In addit ion, two 6- point SM PG profiles (prior to and 2 hours after the morning, 
midday , and evening m eals) shoul d be do cumented on 
non-consecutive days in the week prior to 
the required visits noted in the Schedule o f Activities using CGM -based glucose values ,
(Secti on2). 
Study  parti cipant s who develop severe , persistent hyperglycemia based on prespecified 
thresho lds (see Secti on7.8.2.3 )will receive a new glucose -lowering intervent ion(or rescue 
therapy )based on clinical judgment of the invest igator(see Table BDCM .
4).  Study  parti cipant s 
who need rescue therapy  will cont inue on IP in the trial unt il they co mplete all study  visit s.
Study Period 3
:End-of-Treatment and Safety Follow -Up, Visits 21, 801, 80 2, and 803
All rando mized study  parti cipant s shoul d have a com prehensive efficacy  and safety  evaluat ion 
approximately  1 week after the l ast dose of IP and a safet y follow
-up visit approximately  
6 weeks after the last dose of IP.  During the safet y follow-up study  period, study  parti cipant s
will cont inue CGM andmay be treated with anappropri ate gl ucose -lowering regimen (see Table 
BDCM .4) if necessary .  Study  parti cipant s will also be requi red to return any  remaining study  
diaries and used or unused IP to the invest igative site.
Study  parti cipant s who complete the treatment p eriod will have a comprehensive
End-of-Treatm ent efficacy and safet y assessment (Week 32; Visit 21)approximately 1 week 
I8H-MC-BDCM Clinical Protocol Page 27
LY3209590after the l ast dose of IP and a safet y follow-up assessment (Visit 801) approximately  6 weeks 
after the l ast dose of IP and 5 weeks aft er their End -of-Treatment assessment (Visit 801). During 
the safet y follow-up study  period, study  parti cipant swill cont inue CGM ,andmay be treated with 
anappropri ate gl ucose -lowering regimen (see Table BDCM .4) if necessary . Study  parti cipant s 
will also be requi red to return any  remaining study diaries and used or unused IP to the 
investigat ive site.
Study  parti cipant s who discontinue IP prior to completion of the study  for any  reason shoul d 
also have a co mprehensive End -of-Treatm ent efficacy  and safet y assessment (Vi sit 802) 
approximately  
1week after the last dose of IP or as soon as reasonably  possible thereafter, and 
shoul d have a safet y follow-up assessment (Visit 803) approximately  6 weeks after the l ast dose 
of IP. Study  activit ies at Vi sits 802 and 803 are i dentical to Week 32 (Visit 21) and Vi sit 801, 
respectively .
Study  parti cipant s who discont inue IP prior to study co mpletion will be enc ouraged to rem ain in 
the study  and to com plete any  scheduled study  procedures that occur after their safet y follow
-up 
(Visit803).  Study  parti cipant s remaining in the study  will receive an appropriate rescue 
glucose -lowering regimen.  Table BDCM .4provi des details on the use of glucose -lowering 
medicat ions for rescue and for treatment of acute condit ions.
Study  parti cipant s who discontinue IP for any reason and are unw illing to return for a safety 
follow -upvisit, will be asked to perform an early terminat ion (ET) visit a stheir final study  visit.  
At this visit ,study  parti cipant s will perform procedures listed in the Schedule of Act ivities 
(Secti on 2).
5.2. Number of Participants
Approximately  
536participants will be screened to achieve 375rando mized and 300evaluable 
participants for an est imated total of 100evaluable parti cipants per treatment group.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last study  parti cipant .
5.4. Scientific Rationale for Study Design
This study  will evaluate 2 dosing regimens of LY3209590 in study  parti cipant s with T2DM who 
are al ready  treated wi th a daily  basal insulin. Study parti cipant s will take their last dose of daily  
basal insulin the day  prior to randomizat ion. Treatment will be initiated after randomizat ion with 
either LY3209590 or i nsulin degludec as an act ive comparator. As LY3209590 has a long 
half-life, a weekly dosing regimen is expected to reach steady -state of PK in over  
of treatm ent.  Therefore, the withdrawal  of a daily basal  insulin woul d resul t in loss of glycemic 
control  for several  weeks af ter randomizat ion. Therefore, a loading -dose regimen approach , by 
which an exposure to achi eve co mparable glycemic control to prior basal insulin dose can be 
achieved , followed by  starting at Week 2 
to maintain steady -state exposure.  Subsequent ly,dose adjustments can be made in the init ial 
CCI
CCI
CCI
I8H-MC-BDCM Clinical Protocol Page 28
LY3209590dose individualizat ion phase of the study .See Appendix 7 and section 7.2.1.2 for dos ing and 
administration details.   The 32- week treatm ent durati on is pl anned as the slow dose escal ation 
approach is necessary for LY3209590 to achieve near comparable glycemic efficacy  to prior 
daily  basal insulin .    
Insulin degludec is an unblinded activ e com parator in this study , and will be used to compare the 
effects of LY3209590 on glycemic control, hypoglycemia and weight gain wit h a daily basal 
insulin. 
5.5. Justification for Dose
Following a once -weekly SC administration of LY3209590, the time to reach steady -state 
glucose l evel is estimated between 4 to 10 weeks based on the long half -life of LY3209590.  
Therefore,  weekly dose and gradual  
 dose adjust ment is recommended for LY3209 590 dosing regimen.  
  of LY 3209590 is based on prior basal insulin dose 
convert ing the dose in unit s into mg of LY 3209590 and is based on PK/PD modeling of limited 
SAD and MAD data. Dose adjust mentsare based on average of prior ) fasting 
glucose and hypoglycemia events . Alterati ons to the doses recommended by  these dose 
adjustm ent al gorithms are also under discretion of the invest igator and will take hypoglycemia 
and other study partici pant safet y concerns into account.
The starting dose for insulin deglud ec is the same dose as the bas al insulin that the study  
participant used previously before entering the study. The study  parti cipant will start a titration 
phase based on fast ing glucos e achie vements under this therapy and the presence o f 
hypoglycemia or other safety  concerns. The ti tration will be performed each week. The dose 
adjustm ent al gorithm is adapted from  the well-established Riddle algori thm (Secti on 7.2.1.2 ) 
under discretion o f the invest igator.
Guidance i s provi ded f or the two al gorithms used in dosing LY3209590. There is also guidance 
for conversio n of prior basal insul in dose to LY3209590 loading dose, as well as dosing 
suggest ions for invest igators based on fasting glucose and hypoglycemia of the study  parti cipant 
(Appendix 7 ).
Safety ofstudy  parti cipant s will be closely mo nitored during the early stages of dose titration to 
determine whether adjust ments to the conversio n and dose adjust ment algorithms are needed. As 
additional data em erges, gui dance fro m the Sponsor on these dosing algorithms may be modified
(Appendix 7 )
.
CCI
CCI
CCI
CCI
C
CI
CCI
I8H-MC-BDCM Clinical Protocol Page 29
LY32095906.Study  Population
The study  popul ation will consist of study  parti cipant swith T2DM previously treated with basal 
insulin.   Eligibilit y of study  participant swill be based on the results of the following assessments 
perform ed at scree ning (approximately  Week -2)as described in the Schedule of Act ivities 
(Secti on 2).  The nature of any condit ions present at the time of the initial screening and any 
pre-exist ing condit ions will be documented in the electroni c case report form ( eCRF )
.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permit ted.
6.1. Inclusion Criteria
Study  parti cipant s are eligible to be included in the study  only if they  meet all  of the f ollowing 
criteria at screening:
Type of Study P articipant and Disease Characteristics
[1] Have a diagnosis of T2DM according to the WHO criteria treated wi th basal  
insulin
[2] Are receiving ≥10 uni ts of insulin per day  or ≤1.5 units per kilo of insulin 
per day
Study P articipant Characteristics
[3a] Male study  parti cipant s: 
Men with female partners of childbearing potential must agree to use at least 
one effective method of contracepti on 
(Appendix 5 ) for the duration of the 
study  and f or at least15 weeks (approximately 3half-lives pl us 90 day s)
following the last dose of IP.
[3b] Female study  parti cipant s:  
Women not of child -bearing potenti al may  parti cipate and include those who are:   
Infert ile due to surgi cal sterilizati on (hysterectomy, bilateral oophorectomy, or 
tubal  ligation), congenital ano maly such as Müllerian agenesis; or 
Postmenopausal ,defined as :  
oA wo man at l east 50 years of age with an intact uterus, not on hormone 
therapy , who ha s had ei ther: 
a) Cessat ion of menses f or at l east 1 y ear, or 
b) At least 6 m onths of spontaneous amenorrhea wit h a follicle -
stimulat ing hormone >40 mIU/mL (local laboratory ); or 
oA wo man 55 years or older not on hormone therapy , who has had at l east 
6 months of spontaneous amenorrhea; or 
oA wo man at l east 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy .
I8H-MC-BDCM Clinical Protocol Page 30
LY3209590Women of childbearing potential must agree to remain abstinent (if this is their 
preferred and usual lifest yle), use 1 highly effect ive method of contraception ,or a 
combinat ion of 2 effect ive methods of contraception (Appendix 5 ) starting at 
screening and cont inuing for 15 weeks (approximately 3 half-lives pl us 90 day s) 
afterthe last dose of IP:  
Test negative for pregnancy at screening based on serum pregnancy test, followed 
by a negative urine pregnancy test within 24 hours prior to randomizat ion
(Visit 3)
Not be breastfeeding
[4] A re at least 18 years of age at screening
[5] H ave a baselin e HbA 1cvalue of 6.5% to 10%,inclusive , at screening
[6] Have been treated with a stable regimen of insulin gl argine , insulin levemir
or insulin degludec with or wi thout OAM therapy  for 3 m onths pri or to 
screening and be willing to continue stable dosing throughout the study . 
Acceptable OAMs inclu de up to 3 of the fo llowing:
DPP-
4inhibitors
SGLT -2 inhibitors
biguanides
alpha-glucosi dase inhibitors
sulfo nlyureas
Note: All OAMs m ust be used in accordance with the corresponding local 
product label at the time of screening.
[7] H ave a body  mass index (BMI )between 20and 45 kg/m2, inclusive with no 
significant wei ght gain or l oss in the past 3 m onths ( ≥5%)
[
8] I n the invest igator’s opinio n, are well -motivated, capable, and willing to:
learn how to self
-inject treatm ent, as required for this protocol; visually 
impaired persons who are not able to perform the inject ions must have the 
assistance of a sighted individual trained to inject the IP; persons wit h 
physical limitat ions who are not able to perform the inject ions must have 
the assistance o f an individual  trained to inject the IP;
maintain a study  diary , as requi red for this protocol ;
wear only  the CGM device supplied for use in this study , without 
interrupti on, as requi red in the Schedule o f Activities (Secti on 2) and 
Secti on 9.4.5 ; 
must have a normal wake/sleep pattern such that midnight to 0600 hours 
will reliably reflect a usual sleeping period .
I8H-MC-BDCM Clinical Protocol Page 31
LY3209590Informed Consent
[9]Are able and willing to give signed informed conse nt 
6.2. Exclusion Criteria
Medical Conditions
[
10]Have a diagnosis of ty pe 1 di abetes mellitus or l atent autoimmune diabetes
[11]Are receiving prandial insulin, insulin mixtures, or twice daily basal insulin; 
also if receiving <10 units of insulin per day  or >1.5 uni ts per kilo of insulin 
per day
[12]Have a history  of greater than 1 e pisode of ketoacidosis or hy perosm olar 
state/com a requi ring hospi talizati on in the 6 m onths pri or to screening
[
13]Have had any  episodes of severe hypoglycemia and/or hypoglycemia 
unawareness wit hin the 6 months prior to screening
[
14]Cardi ovascular (CV):  have had any of the fo llowingCV condi tions: acute 
myocardial  infarct ion, New York Heart Association Class III or IV heart 
failure ( Appendix 6 ), or cerebrovascular accident (stroke)
[15] Gastrointestinal:  have undergone gastric bypass (bariatric) surgery  or 
restri ctive bariatric surgery ( e.g., Lap -Band®) pri or to screening
[
16]Hepati c:  have acute or chronic hepat itis, or obvious clinical signs or 
symptoms of any other liver disease except non -alcoholic fatty  liver di sease 
(NAFLD) (i.e., study part icipant s with NAFLD are eligible for 
participat ion), and/or h ave elevated liver enzyme measurements, as 
determined by the central laboratory  at screening and as indicated below:
Total  bilirubin >2x the upper limit of normal (ULN), or
ALT/serum glutamic py ruvic transaminase (SGPT) >2.5x ULN, or
Aspartate aminotransfe rase (AST)/serum  glutamic oxal oacetic 
transaminase (SGOT) > 2.5x ULN
[
17]Renal:  have an estimated glo merular filtrat ion rate (eGFR )
<
30mL/min/1.73 m2, calculated by  the Chroni c Kidney Disease -
Epidemi ology equati on, as determined by the central laborator y at screening
[18]Have experienced significant weight loss or gain (>5%) in body  weight ,
3months pri or to screening (Visit 1)
[19] Have active or untreated malignancy, or have been in remissio n from 
clinically significant malignancy (other than basal cell or squamous cell skin 
cancer) for less than 5 y ears or are at increased risk for developing cancer or 
a recurrence of cancer in the opinio n of the investigator
[
20]Have known hypersensit ivity or allergy  to any  of the study  medicat ions or 
their excipi ents
I8H-MC-BDCM Clinical Protocol Page 32
LY3209590[21] Have any other seri ous di sease or condi tion (f or exam ple, known drug or 
alcoho l abuse or psy chiatri c disorder) that, in the opinio n of the investigator, 
woul d pose a si gnificant risk to the study  parti cipant , precl ude the study  
participant from following and com pleting the protocol, or interfere with the 
interpretati on of  safety, efficacy, or PD data
[
22]Have had a blood transfusio n or severe blood loss within 3 mo nths prior to 
screening or have any hematologic condit ion that may interfere with H bA1c 
measurement ( e.g., hem oglobinopathy , hem olytic anemia, sickle -cell 
disease)
[23] Have a significant history  of alcoholism or drug abuse as judged by  the
investigator or consuming more than 24 g of alcohol per day  for males or
more than 12 g of alcoho lper day  for females
[24]Have fast ing Triglyceride levels above 400 mg/dl or non -fasting 
Triglycerides above 600 mg/dl at screening.
Prior/Concomitant Therapy
[25] Drugs which may significant ly affect glycemic control ( e.g., niacin [allowed 
if<1.0g/day ], bile acid sequestrants)
[
26]Are receiving chronic (>14 day s) systemic glucocorticoid therapy  (excluding 
topical, intraocul ar, intranasal, or inhaled preparations) or have received 
such therapy  for >14 days wi thin the m onth preceding screening
[
27]Are current ly taking or have taken within the 3 months preceding screening, 
prescri ption or over -the
-counter medicat ions to promote weight loss.  Study  
participant s who participate must agree not to init iate a diet and/or exercise 
program during the study  with the intent of reducing body  weight other than 
the lifest yle and dietary measures for diabetes treatment
[28] Are using or have used blood pressure -lowering medicat ion at a dose that 
has not been stable for 1 month prior to screening .
Prior/Concurrent Clinical Trial Experience
[
29] A re current ly enrolled in any other clinical study  involving an IP or any 
other ty pe of medical research ,judged not to be scient ifically or medically 
compatible with this study
[
30] H ave participated, within the las t 30 days in a clinical  trial invo lving an IP. 
If the previous IPhas a long ha lf-life, 3 months or 5 half -lives (whichever is 
longer) should have passed
[
31] H ave previ ously com pleted or withdrawn fro m this study  or any  other study  
investigat ing LY3209590.
I8H-MC-BDCM Clinical Protocol Page 33
LY3209590Other Exclusions
[32] A re invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, 
or sibling, whether bio logical  or legally adopted
[
33] A re Eli Lilly and Co mpany ( Lilly )empl oyees or are em ployees of any 
third-party  involved in the study  who requi re excl usion of  their em ployees
6.3. Lifestyle Restrictions
Per the Schedule of Act ivities (Secti on2), qualified medical staff will provide diabetes
management counseling, which will include instructions on diet and exercise and educat ion 
about the signs, symptoms, and tr eatment of hypoglycemia, should it occur. Study  parti cipant s 
shoul d cont inue their usual exercise habits and generally  follow a healt hymeal plan (with 
consistent meal size and t ime of day) throughout the course of the study . Dietary  counseling 
may be reviewed throughout the study , as needed.
Prescri ption or over -the
-coun ter (OTC) m edicat ions that promote weight loss are exclusionary  if 
used wi thin 3 m onths prior to screening (study  entry), or between screening and rando mization at 
Visit 3 (see Secti on2).  These medicat ions are also not allowed at any  time during the treatment 
period.  If started after randomizat ion, they should be immediately wit hdrawn.  In addi tion, study  
participant s should not receive an intensive diet/exercise program wit h the intent of reducing 
body  weight at any  time during the study , other than the lifest yle and dietary measures for 
diabetes treatm ent.
Study  parti cipants sho uld be instructed not to donate blood or blood products during the stud y or 
for 4 weeks fo llowing the study .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened once . The interval between screening and rescreening should be at least 4 weeks.  A
new informed consent form ( ICF
)must be signed at the time of rescreening andthe study  
participant will be assigned a new ident ificat ion number. A single r epeat t esting of suspe cted 
erroneous/ spuri ous central  laboratory resul tsis allo wed wi thout rescreening the study  parti cipant .
I8H-MC-BDCM Clinical Protocol Page 34
LY32095907.Treatment s
7.1. Treatments Administered
LY3209590 will be administered once weekly as subcutaneous (SC) inject ions. Each study  
participant will receive 1 i nject ion each week, as described in Table BCD M
.3.  SC i nject ions of 
LY3209590 will be administered rotating between left and right abdo minal regio ns and upper 
and lower quadrants. During the first 8 weeks, treatment will be administered by the study  staff ,
while study  parti cipant s receive educat ion and training on how to reconstitute and self
-administer 
LY3209590 .  During Weeks 9 to 12, LY3209590 will be reconst ituted and administered at the 
site by  the study  participant under supervisio n of the site personnel to assure that the study  
participant is capable of self -administrati on.  During Weeks 13to 31, LY3209590 will be 
self-administered by  the study  parti cipant at home, or optionally can be administered once 
weekly by  site personnel .
Insulin degludec will be administered once daily  at approximately the same time of day , rotating 
between l eft and ri ght abdominal  regions and upper and l ower quadrants .
Study  parti cipant s will receive treatment with LY3209590 by 1 of 2 algorithms.   Table BCD M.3
shows the treatment regimens.   See Section 7.2.1 for details on dosing algorithms and Secti on
7.8.1 for transit ioning to treatment after study  compl etion.
Table BCDM.3. Treatment Regimens
RegimenDose
Randomization through Week 32
LY Dose Algorithm 1 LY injection
LY Dose Algorithm 2 LY injection
Insulin degludec Insulin degludec injection
Abbreviations:  LY = LY3209590 .
The invest igator or his/her designee is responsible for the fo llowing:   
explaining the correct use of the investigational agent(s) to the study  parti cipant
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
at the end of the study ,returning all unused medication to L illy, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law
7.1.1. Packaging and Label ing
LY3209590 will be provided as  of lyophilized powder in a vial. Reconst itution with 
sterile water or 0.9% sodium chloride will be required pri or to dosing.
CCI
I8H-MC-BDCM Clinical Protocol Page 35
LY3209590Insulin degludec will be provided as a 100 U/mL sol ution in a 3 -mL prefilled pen.
All IP materials must be stored at the invest igative sites, according to the instructions provided 
onthe product label, in a locked and secure place. Insulin must not be frozen. Unused study
treatm ents will remain in a locked and secured place at the investigative site s, according to
instructi ons provi ded on the product label, or according to written instruction from the Sponsor,
until returned to the Sponsor or destroyed.
Clinical study materials will be labeled according to the country ’s regul atory  requi rements.
7.2. Method of Treatment Assignment
Study  parti cipant s who meet all criteria for enrollment will be rando mized to open -label
treatm ent at Visit 3.  Assignment to treatment groups will be determined by a 
computer -generated random sequence using an interactive web -response system (IWRS).  The 
IWRS will be used to assi gn open -labelIP to each study  participant .  Site personnel will confirm 
that they  have l ocated the correct IP by  entering a confirmat ion number found on the IP label 
into the IWRS.
To achieve between -group com parabilit y for site factor, the random ization will be stratified by  
country , baseline HbA1c (<8.5%, ≥8.5%), country, SU(yes/no), and baseline BMI (<30, ≥30).  
The rando mizat ion scheme will be performed using IWRS ,which will ensure balance between 
treatm ent arm s.
7.2.1. Selection and Timing of Doses
Study  parti cipants will be rando mly assigned to a LY3209590 dose via Algorithm 1 or 
Algori thm 2.  The doses will be administered at approximately the same t ime and day each week.  
The actual  date and time of all dose administrations will be recorded in th e subject’s diary (or 
study  participant ’s medical record when administered at the site) and in the e CRF. Insulin 
degludec will be administered same t ime each day ,adjusted per m odified Riddle algorithm
(Secti on 7.2.1.2 )
.
If a study  parti cipant misses a scheduled dose of LY3209590, it should be administered a ssoon 
as possible, but no later than 3 days after the scheduled administration.  If more than 3 days have 
elapsed since the scheduled administration, the dose should be skipped and the next inject ion 
will occur at the next scheduled day and time. Study  participant s who miss a dose of insulin 
degludec shoul d inject thei r daily dose during waking hours upon discovering the missed dose. 
Instruct study  parti cipant s to ensure that at least 8 hours have elapsed between consecut ive 
insulin degludec injections (T resiba USPI). 
7.2.1.1. LY3209590 Algorithm s
Guidance is provided for conversio n of prior basal insulin dose to LY 3209590 loading dose and 
initial weekly dose ( Appendix 7 ).  Dose adj ustment is based on study  participant s’ pri or fasting 
glucose and hypoglycemic events (Appendix 7 ).  Al terati ons to the doses recommended by  these 
dose adjustment algorithms are allowed in situat ions where study  parti cipant safet y is a concern 
or where adjust ments do not show the desired therapeuti c effect , after consultation with Lilly . 
I8H-MC-BDCM Clinical Protocol Page 36
LY3209590As addi tional data em erges, the gui dance from  the Sponsor on these dosing algorithms may be 
modified.
7.2.1.2. Insulin Degludec
Insulin degludec will be initiated at the same dose as the total daily basal insulin dose already  
administered, or in accordance with the locally  approved product l abeling if different.   
Thereafter, a dosing algorithm adapted fro m Riddle et al . 2003 will  be used by  invest igators for 
adjusting insulin degludec to target an FBG ≤100 mg/dL ( <5.6mmo l/L) in order for study 
participant s to achieve glycemic goals o f anHbA1c value <7.0% and a pre-prandial capillary 
plasma gl ucose (PG) between 71and130 m g/dL (3.9 to 7.2 mmo l/L; ADA 2011) .  In si tuations 
where study  parti cipant safet y is a concern or where dose adjust ments have not had the desired 
therapeuti c effect, invest igators may only make increased adjustments to the dose of insulin 
degludec recommended by the dose -adjustment algori thm after consul tation wi th Lilly.
At the time of si te visi t or tel ephone visit, the investigator will assess the study  parti cipant ’s 
glycemic control for the previous week and, if necessary, inform the study  parti cipant about any 
needed dose adjustment.   The dose will be based on the study  parti cipant ’s blood gl ucose value . 
Adherence to the dosing algorithm provided for this study  is requi redfrom Visit 3 
(randomization) up to Visit 21(Week 32, inclusive )and will be mo nitored peri odically  by the 
study  team . Dose increases may be m ade at weekly  intervals and no sooner than 5 days 
following the last dose increase .  In som e cases, study  parti cipant visits could occur sooner than 
5 day s apart due to the allowable visit window; however, there should be no dose increase if at 
least 5days have not elapsed since the previous dose increase.  In contrast, the insulin degludec
dose may be reduced at any  time on the j udgment of the invest igator. Any deviat ions from this 
guidance must be approved by  Lilly .
The insulin dose increase algori thm is adapted from Riddle et al. 2003 and will be determined 
based on the definit ion of what is termed the “Algorithm FBG .”  The Algorithm FBG is the 
median of the FBG ( determined from self-monitoring of blood glucose [SMBG ]) of D ays5, 6,
and 7 since the last insulin dose increment .  If the interval since the last dose adjustment has been 
longer th an 7days, the dose increase is determined by  the median of the FBG of the last 3 day s. 
If the study  parti cipant only measured their FBG on 2 of the last 3 days, then the lesser of those 
2FBG values should be used as the Algorithm FBG.  If only 1 FBG measurement is available 
for the l ast 3 day s, then the invest igator should use his/her discretion in determining whe ther 
there shoul
d be a dose adj ustment based on that single FBG value.
As it is desi red to achieve glycemic goals in as many  study  parti cipant s as possible, 
contingencies are provided to accommodate prespecified protocol visits and toincrease the dose 
of insulin degludec in a t imely manner.  Therefore, if the last dose increment was 5 days prior, 
then the dose increment is determined by the Algori thm FBG, which is the lesser of the 2 FBG 
values from Day 4 and D ay 5. If the dose increment was 6 days prior,then the Algo rithm FBG 
is the lesser of the 2 FBG values fro m Day 5 and D ay 6.  In both of these cases, if only 1 of the 
2FBG values is available, then the invest igator should use his/her discretion in determining 
whether there should be a dose adjust ment based on that single FBG value.
I8H-MC-BDCM Clinical Protocol Page 37
LY3209590The dose increase algorithm is defined as fo llows:
If the Algorithm FBG is 101 to 120 mg/dL (5.6 to 6.7 mmo l/L), increase the dose 
by 2 U.
If the Algorithm FBG is 121 to 140 mg/dL (6.8 to 7.8 mmo l/L), increase the dose 
by 4 U.
If the Algorithm FBG is 141 to 180 mg/dL (7.9 to 10.0 mmo l/L), increase the 
dose by  6 U.
If the Algorithm FBG is 180 mg/dL (10.0 mmo l/L), increase the dose by  8U.
The treat-to-target FBG is ≤100 m g/dL (<5.6 mmol/L).  The insulin dose will not be in creased if 
any SMBG was docum ented at ≤70 mg/dL (<3.9 mmo l/L) at any  time in the preceding week.  
Dose decrease s of 2 to 4 U per adjust ment may be permitted if multiple episodes of 
hypoglycemia wit h SMBG ≤70 m g/dL ( <3.9 mmo l/L) were recorded, if severe hyp oglycemia 
(requiring assistance) occurred, or if any  SMBG was docum ented at ≤54 mg/dL (≤3.0 mmo l/L) 
in the preceding week.
7.3. Blinding
This study  is an open -label study . Invest igators, site personnel and study  parti cipant will be 
aware of the treatment allocat ion. Due to the differences in administration of LY3209590 (once 
weekly) and the comparator ( degludec given once daily) blinding the treatment assignment 
woul d be impossible for these titratable medicat ions.
7.4. Dosage M odification
Dosing will be individualized based on FBG. SeeAppendix 7 andsection7.2.1.2 for details of 
dose m odific ation.
7.5. Preparation/Handling/Storage/Accountability
The invest igator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepanci es are reported and 
resolved before use of the study  treatm ent.
ensuring that only participants enro lled in the study may receive study treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study 
treatm ents m ust be stored in a secure, environmentally controlled, and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
the invest igator, inst itution, or the head of the medical institution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion and final disposit ion records).
The study  site must store LY3209590 and insulin degludec under refrigerated condi tions (2 °C to 
8°C) until use.  Insulin must not be frozen. In -use storage condit ions m ust be fo llowed  according 
I8H-MC-BDCM Clinical Protocol Page 38
LY3209590to the storage condit ions provided on the label .  Study  parti cipants will be provi ded wi th cartons 
containing the required nu mber of vials or pens at clinic visits as shown in the Schedule of 
Activities (Section 2).  They  will receive insulated bags with cooling gel packs for use in 
transporting the cartons fro m the site to hom e.  Dry  ice shoul d not be used for cooling.
Unused medications will remain locked and securely  stored under refrigerated condit ions (2 °C to 
8°C) at the invest igative site unt il returned to the Sponsor or destroy ed according to written 
instructi on from the Sponsor.
7.6. Treatment Compliance
The assessment of treatment compliance with IP (LY3209590 or insulin degludec) will be 
determined by the fo llowing:
Inform ation about the once weekly IP inject ions will b e entered into the study  parti cipant
diary by the study  parti cipant and reviewed by the site personnel at each study  visit .This 
inform ation will be co llected in the eCRF;
IP accoun tabilit y will be checked according to the Schedule of Act ivities (Section 2).  
Study  parti cipant s will be instructed to return all dispensed vials, any unused pens and/or 
all empty  cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.  
Other aspects of compliance will also be assessed at each visit, including the study  parti cipant ’s 
adherence to the visit schedule, co mpliance with the concomitant OAM requirements and other 
medicat ion guidance (Secti on 7.7), com pletion of study  diaries, resul ts of SMBG, and any other 
param eters the invest igator considers necessary.  Study  participant s considered to be poorly  
compliant wi th their medicat ions and/or study  procedures (for example, missed visit s or specific 
diagnosti c tests) will  receive addi tional training and instructi ons, as requi red.
7.7. Concomitant Therapy
Study  parti cipant s wil l be permitted to use concomitant medications that they  requi re during the 
study , except excluded m edicati ons described in Secti on 6.2(Excl usion Criteria) and Secti on 
7.7.1 to Secti on 7.7.4 below .In addition, certain permitted medicat ions (for example, treatments 
for blood pressure or dyslipidemia) described in Section 7.7.5 and Section 7.7.6 may be 
continued, but not changed, during the course of the study .
Invest igative site staff will inform study  parti cipant s that they must consult with the invest igator 
or a designated site st aff member upon being prescribed any new medicat ions during the study , 
except when init iated for treatm ent of m edical  emergencies.  Any addit ional medicat ion initiated 
during the course of the study  (including OTC drugs, such as aspirin) must be documented , and 
the name of the drug and the date(s) of administratio n must be recorded in the study  parti cipant ’s 
diary and on the “Concomitant Medicat ions” section of the eCRF.  In addition, for permitted 
concomitant glucose -lowering agents, the dosage will also b e docum ented and collected.
I8H-MC-BDCM Clinical Protocol Page 39
LY3209590Non-study  medicat ions taken by study  partici pants who are screened but not randomized will not 
be reported to Lilly unless an SAE or AE occurs that the investigator believes may have been 
caused by  a study  procedure.
Table BDCM .4provides a summary  of criteria for use of concomitant medicat ions that may 
interfere wi th planned assessments during the study .
Table BDCM .4. Criteria for Use of Concomitant Medications that may Interfere with 
Efficacy and Safety Assessments in Study BDCM
Drug Class Use During 
Screening/Lead -InConditions for Use After Randomization
Acute 
therapy aRescue 
therapy During Safety 
Follow -up Period
Drugs with approved weight loss 
indicationbExcluded N N/A N
Systemic glucocorticoid therapy c Excluded except for 
acute therapy aY N/A N
Antihy perglycemia medications
GLP-1 RAs Excluded N Y Y
DPP-4 inhibitors Permitted N Y Y
SGLT2 inhibitors Permitted N/A Y Y
Insulins and insulin mixtures Daily  basal insulins 
Permitted. All 
others Excluded 
except for acute 
therapy aY Y Y
Meglitinides Excluded N N Y
Alpha-glucosidase inhibitors Permitted N Y Y
Sulfon ylureas Permitted N N Y
Thiazolidinediones Excluded N N N
Metformin d Permitted N Ye Y
Abbreviations: DPP-4 = dipeptidyl peptidase -4; GLP -1 RA = glucagon -like peptide -1 receptor agonist; N = no ;
N/A = not applicable; SGLT2 = sodium -glucose cotransporter 2; Y = Yes.
aAcute therapy = treatment for up to 14 days.
bIncludes Saxenda ®(liraglutide 3.0 mg), Xenical ®(orlistat), Meridia ®(sibutramine), Sanorex ®(mazindol), 
Adipex -P® (phentermine), Belviq® (lorcaserin), Qsymia ®(phentermine/topiramate combination), Contrave ®
(naltrexone/bupropion) or similar other body weight loss medications including over-
the-counter medications 
(e.g., allī® [orlistat 60 mg capsules] ). 
cDoes not apply to topical, intraocular, intranasal, intra -articular, or inhaled preparations; 
dSwitch ingmetformin manufacturers is allowed, as long as the dosage is the same.  Changing to a metformin 
formulation with a different action profile ( i.e., from short -acting to long -acting metformin) is not permitted.
eFor rescue therapy, metformin dose may be increased if the dose is below maximum approved dose per country -
specific label.
7.7.1. Antihyperglycemia Medications
Insulin lispro as prandial treatment or i nsulin degludec are the preferred cho ice for rescue 
therapy  in study  parti cipant s rando mized to LY3209590 or insulin degludec .  The only other
glucose -lowering agents allowed as rescue therapy during the study are conco mitant m etformin, 
I8H-MC-BDCM Clinical Protocol Page 40
LY3209590SLGT2 inhibitors, DPP-4 inhibitors, SU and a lpha-glucosi dase inhibitors .  In addi tion,insulins 
other than insulin degludec may be used for short -term (up to 14 days) management of medical 
emergencies pri or to study  entry  and during the study .  Rescue therapy  with other 
glucose -lowering agents, may be medically  indicated in certain situat ions after randomizat ion
(Table BDCM .4).  These situat ions are described in Section 7.8.2.3 (severe, persistent 
hyperglycemia) and in Sect ion8.1.1 (early discontinuat ion of IP
).
If any new glucose -lowering medicat ion is initiated after randomization at Visit 3, other than IP, 
rescue therapy , or short -term use of insulin for medical emer gencies, the study  participant will be 
requi red to immediately discont inue the medication and the appropriate study deviat ion report 
will be generated.  Any  such vi olation of the protocol that lasts longer than 14 day s will  exclude 
the study  parti cipant from the per -protocol (PP) populat ion for analyses.
7.7.2. Concomitant Antihyperglycemia Medication
Study  parti cipant s treated with metformin in this study  must be on a stable dose for at least 
3months pri or to screening.  The prescreening dose and formulation (sh ort-acting or long -acting) 
must be maintained from the time of screening through the study  participant ’s last visi t, except as 
requi red for rescue therapy  (Secti on 7.8.2.3 ).
Where appropriate, allowable OAM therapy  may be obtained l ocally by  the Lilly affiliate in the 
participat ing country fro m local commercial  supplies and distributed to sites.  It is acceptable for 
study  participant s to continue obtaining their OAM therapy  by previ ous prescribing process.  In 
the United States and Puerto Rico, a prescript ion card will be available for study participant s to 
obtain their OAM therapy  with a prescri ption.
Dose adjust ments of allowable OA M therapy  are permi tted af ter randomizat ion (during the 
treatm ent peri od) under the following circumstances:
situations that requi re short -term treatm ent interrupti on in line wit h the product labeling 
for each respective country;
situations that requi re do se adj ustment or di scont inuation per country -specific label, for 
example, in the case of reduced eGFR;
in the case of increased hypoglycemia risk during the treatment period (as described in 
Secti on 7.8.2.2 ).
Dose reduction of allowable OAM therapy  during the tri al shoul d be properly  docum ented.
In study  parti cipant s who require rescue therapy , dose increase of allo wable OAM therapy  is 
permitted, but the dose and the reason for change must be properly  documented in the eCRF.
Guidance f or treatm ent during the safet y follow -up peri od is provi ded in Sect ion 5.1.1 (Study 
Period 3: Safet y Follow-up, Vi sit 801).
7.7.3. Medications that Promote Weight Loss
Prescri ption or OTC medicat ions that promote weight loss are exclusio nary if used wi thin the 
3months pri or to screening, or any  time after screening (see Se ction7.7).  If started after 
I8H-MC-BDCM Clinical Protocol Page 41
LY3209590screening, these medicat ions should be stopped immediately.  In addit ion, study  parti cipant s 
shoul d not receive an intensive diet/exercise program with the intent of reducing body  weight at 
any time during the study , other than the lifestyle and dietary measures for diabetes treatment 
(see Secti on6.3).
7.7.4. Systemic Glucocorticoids
Chronic systemic glucocortico id therapy (excluding to pical, intraocular, intranasal , or i nhaled 
preparati ons) is exclusio nary if used >14 consecut ive days during th e 1-month peri od before 
screening or between screening and rando mizat ion at Visit 3.  Study  parti cipant s who require 
>14 consecutive days of therapy  with these m edicati ons after randomizat ion will be excluded 
from the PP popul ation for analyses.
7.7.5. Antihypert ensive Medications
If used, anti -hypertensive therapy  should be kept stable throughout the trial to allow assessments
of the effect of rando mized therapies on blood pressure .
7.7.6. Dyslipidemia Medications
If used, dyslipidemia therapy shoul d be kept stabl e thro ughout the trial to allow assessments of 
the effect of rando mized therapies on lipid endpo ints.
7.8. Treatment After the End of the Study
7.8.1. Treatment After Study Completion
Invest igational Product will not be m ade available to study  parti cipant s after conclusio n of the 
study
Beginning on the evening of the last treatment visit ( Visit 2 1[Week 32]or ETvisit), study  
participant s will resume their previous basal insulin therapy . As washout of LY may take up to 
10 weeks to complete, previous basal insulin therapy  will be institutedusing the Riddle 
algorithm as need based on FBG (Secti on 7.2.1. 2.).For example
,no insulin would be required 
until the study  parti cipant ’s blood glucose increases to >100 mg/dL , and then daily  basal insulin 
woul d be ini tiated and adj usted based on weekly algorithm FBG.
Study Participant s treated with LY3209590:
Study  parti cipant s will receive the last injection o f LY3209590 at Week 31of the study  and will 
switch back to thei r previ ously used basal  insulin after Visit 21.  Since LY3209590 has a 
half-life of approximately   of the 
original  insulin dose and   of the original  insulin dose.  
Therefore, a slow up -titration of  their previ ously used basal  insulin is necessary to prevent 
hypoglycemia due to overlapping insulin act ion.  The pre -study  basal insulin shoul d be started at 
a dose of 10 I.U. at Visit 22 with a F
BG of above 120 mg/dL for 3 consecutive days or as soon as 
the study  parti cipant s FBG is above 1 80mg/d Lfor 3 consecut ive days.  Thereafter ,an 
CCI
CCI
CCI
CCI
I8H-MC-BDCM Clinical Protocol Page 42
LY3209590up-titration according to the modified Riddle algorit hm or any  country  specific label should be
applied.
Study P articipant s treated with Insulin Degludec:
Study  parti cipant s assigned to the insulin degludec treatment arm will switch back to their 
pre-study  basal insulin after Visit 21.  If their pre -study  Basal  insulin was insulin degludec they  
can continue with the same dose used unt il Visit 21of the study .  If they  switch back to another 
basal insulin (e.g. insulin Glargine), study  parti cipant s should inject a daily dose, which is 20% 
lower than the last dose of insulin degludec used before Visit 21and titrate under supervisio n of 
the invest igator using the country -specific label for their pre -study  basal insulin.
All study  parti cipant s will cont inue to wear a continuous blood glucose monitor during the 
5-week fo llow -up peri od to ensure a safe tra nsition back to their pre -study  basal  insulin.
7.8.2. Special Treatment Considerations
7.8.2.1. Standards of Medical Care
Invest igators and other study  team  members are expected to treat study participant s according to 
the nat ionally established standards o f care for diab etes m anagement in respect ive participating 
countri es, except where that treatment would be in conflict with the protocol -provi ded treatm ent 
requi rements. If there are no local standards of care for diabetes, the invest igators should fo llow 
current publis hed standards of care from the American Diabetes Association (2016) and the 
European Associat ion for Study  of Diabetes (Inzucchi et al. 2015) during their study  
participant s’ participat ion in this study .
This sect ion provi des gui dance on management of epis odes of hypoglycemic events and events 
ofsevere, persistent hy perglycemia. For effect ive implementation of measures described here, it 
is important that study  parti cipant s, and their caregivers, if applicable, be well -educated about the 
signs and symptom s of hyperglycemia ( for example , severe thirst, dry  mouth, f requent 
micturit ion, or dry  skin) and hypoglycemia ( for example , intense hunger, sweat ing, tremor, 
restlessness, i rritabili ty, depressi on, headaches, di sturbed sl eep, or transient neurological 
disorders). Study  parti cipant s shoul d be instructed to contact the invest igative site in the event of 
severe, persistent hyperglycemia or severe hypoglycemia between study visits.
7.8.2.2. Management of Increased Hypoglycemia Risk
The risk associ ated with the allowable OAMs is low since all but the sulfonylureas are non -
secretagogues; therefore, clinically relevant increases in the risk of hypoglycemia due to the 
OAMs are not expected in this trial.  The effects of LY3209590 on hy poglycemia are not known 
and an objective of the study  is to assess the risk of hypoglycemia in study  parti cipant s receiving 
LY3209590.
The study  uses real -time CGM to con tinuously  monitor potenti al hypoglycemic events. In case 
of a hypoglycemic event ,study participant s will be proact ively warned by an alarm and are 
instructed to immediately ingest rapidly absorbable carbohydrates. This safet y measure 
minimizes the risk of severe hypoglycemic events during the complete study  durati on.
I8H-MC-BDCM Clinical Protocol Page 43
LY3209590In this study , increased risk o f hypoglycemia is d efined as having a single episode of severe 
hypoglycemia or having more than 1 epi sode of docum ented symptom atic hypoglycemia within 
a 1-week period at any t ime during the treatment period .
In cases where a study  parti cipant experiences hypoglycemia as des cribed above, to confirm the 
increased risk, the study  sites m ustensure that the study  participant has been fully com pliant 
with the assigned therapeutic regimen and also that there is no evidence of other possible causes 
of hypoglycemia ( e.g., omissio n of meal, unexpected increase in exercise) .
Study  parti cipant s fulfilling the definit ion of increased risk of hypoglycemia should first decrease 
their OAM dose (especially SU), followed by discontinuat ion of OAM therapy , if needed.  If the 
study  participant continuesto experience hypoglycemic events after the discont inuat ion of OAM 
therapy , the invest igator should reduce the dose according to the appropriate algorithm 
(Secti on7.2.1.2 ) or discont inue the study  parti cipant from IP.
7.8.2.3. Management of Study P articipant s with Severe, Persistent 
Hyperglycemia during the Treatment Period
An addit ional therapeut ic intervent ion shoul dbe considered in study  parti cipant s who develop 
severe, persistent hyperglycemia after randomizat ion based on the following criteria (reference 
FDA Draft Guidance 2016):   
a)average FPG >270 mg/dL (>15.0 mmo l/L) over any 2- week peri od or l onger during the 
first 6 weeks postrandomizat ion; or
b)average FPG >240 mg/dL (>13.3 mmo l/L) over any 2- week peri od or l onger from  
Week 6 to Week 12 postrando mizat ion; or
c)average FPG >200 mg/dL (>11.1 mmo l/L) over any 2- week peri od or l onger from  
Week 12 to Week 18 postrando mization.
Invest igators should first confirm that the study  parti cipant does not have an acute condit ion 
causing severe hyperglycemia and, after the first 12 weeks of the study , that the study  participant
is fully co mpliant with the assigned therapeut ic reg imen.  The invest igator will decide, in 
collaboration with the responsible clinical research physician (CRP )and in consul tation wi th the 
study  participant , on an appropriate glucose -lowering intervent ion (rescue intervent ion) after 
consideri ng relevant clinical criteria. In general, insulin degludec will be the preferred rescue 
therapy  for study  parti cipant s assigned to LY3209590. See Table BDCM .4for allowed 
medicat ions.  Study  parti cipant s who receive a new intervent ion for hyperglycemia management 
shoul d also continue administering IP for the remaining period in the trial.
7.8.2.4. Emergency Situations
In em ergency situat ions, it may be necessary  for study  parti cipant sto change their dose of OAM 
and/or be treated with a non -study  insulin.  Thi s will  be allowed f or up to 2 weeks total prior to 
Visit 21(Week 32).  If multip lesituationslast longer than 2weeks total prior to Visit 21
(Week 32), a decisio n to keep the study  partici pant in the study  shoul d be made only after 
consultation between the invest igator and the Lilly CRP .  The decisio n shoul d be documented by  
a note to the invest igator’s file.
I8H-MC-BDCM Clinical Protocol Page 44
LY32095908.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible r easons leading to permanent discontinuatio n of IP:  
Subject Decision
othe study  parti cipant or the study  parti cipant ’s designee, for exa mple, parents or legal 
guardi anrequests to discontinue IP.
Discontinuation due to a hepatic event or liver test abnormality.   
oStudy  parti cipants who are discontinued fro m IPdue to a hepatic event or liver test 
abnorm ality should have addi tional hepatic safet y data collected via eCRF.
Discontinuati on of  the IPfor abnormal liver tests should be considered by the 
investigator when a study  participant meets one of the fo llowing condi tions af ter 
consultation wit h the Lilly designated medical monitor:
ALT or AST >8X ULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o >1.5
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
alkaline phosphatase (ALP) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, study  partici pants will be discont inued fro m the IPin the fo llowing 
circumstances:
ifa study  parti cipant is inadvertently enro lled and it is determined that continued 
treatm ent wi th IP woul d not be m edically appropriate (see Section 8.1.3 )
if a study  participant is diagnosed with an act ive or untreated malignancy (other than 
basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate 
cancer) after randomization
if a study  parti cipant is diagnosed by the invest igator with ac ute or chronic pancreat itis
if a study  parti cipant is diagnosed with C -cell hyperpl asia or medullary thyroid carcino ma
after randomizat ion
I8H-MC-BDCM Clinical Protocol Page 45
LY3209590if the invest igator or sponsor decides that the study participant shoul d be wi thdrawn from  
IP; if the invest igator de cides to permanent ly discont inue IP because of an SAE or a 
clinically significant laboratory  value, Lilly or i ts designee shoul d be alerted 
immediately .
Study  parti cipant s discont inuing fro m the IPstudy treatm ent prem aturely  for any reason shoul d 
complete AEand other fo llow-up procedures per Section 2(Schedule of Act ivities), Section 9.2
(Adverse Events), and Section 9.4(Safet y) of this protocol .
Study  parti cipant s who stop the IPpermanent ly may receive another gl ucose -lowering 
intervent ion, if appropri ate,and will cont inue partici patingin the trial according to the protocol 
to collect all planned efficacy and safet y measurements.
8.1.2. Temporary Discontinuation from Study Treatment
In certain situat ions after rando mizat ion, the investigator may need to temporarily discont inue 
(interrupt) IP(for example, due to an AE or a clinically significant laboratory value).  If IP
interrupti on is due to an AE, the event is to be documented and fo llowed according to the 
procedures in Secti on 9.2ofthis protocol .  Invest igators should inform the Sponsor that IPhas 
been tem porarily interrupted.  Every  effort shoul d be made by the invest igator to maintain study  
participant s on IPand to restart IPafter any  temporary  interrupti on, as soon as i t is safe to do so.  
The data related to temporary  interrupti on of  IPwill be docum ented in source doc uments and 
entered in the eCRF.
8.1.3. Discontinuation of Inadvertently Enrolled Study Participant s
If the sponsor or i nvest igator ident ify a study  partici pant who did not meet enrollment criteria 
and was inadvertent ly enro lled, then the study  participant shoul d be di scontinued from study  
treatment unl ess there are extenuat ing circumstances that make it m edically  necessary  for the 
study  participant to conti nue on study  treatm ent.  If the invest igator and the sponsor CRP agree 
that it is medically  appropri ate to continue, the investigator must obtain documented approval 
from the sponsor CRP to allow the ina dvertent ly enro lled study  parti cipant to continue in the 
study  with or wi thout treatm ent wi th IP. Safet y follow up i s as outlined in Sect ion2(Schedule 
of Activities), Section 9.2(Adverse Events), and Section 9.4(Safet y) of the protocol .
8.2. Discontinuation from the Study
Study  parti cipant s will be discont inued in the fo llowing circumstances:
if a study  parti cipant is diagnosed with any t ype of diabetes mellitus other 
than T2DM
if a female study  parti cipant beco mes pregnant , enrollment in any other 
clinical study  involving an IPor enrollment in any  other ty pe of medical 
research judged not to be scient ifically or m edically  com patible with this 
study
I8H-MC-BDCM Clinical Protocol Page 46
LY3209590participat ion in the study needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce (GCP)
investi gator decisio n
othe invest igator decid es that the study  parti cipant shoul d be discontinued
from thestudy
oif the study  parti cipant , for any  reason, requi res treatm ent wi th another 
therapeuti c agent that has been demo nstrated to be effect ive for treatm ent 
of the study  indicati on, discont inuat ion from the study  occurs pri or to 
introducti on of  the new agen t
study  participant decisio n
othe study  parti cipant /study  participant ’s designee, for example, parents or 
legal guardian requests to be withdrawn fro m the study
Study  parti cipant s discont inuing fro m the study  prem aturely  for any reason shoul d com plete AE
and other safet y follow
-up per Secti on 2(Schedule of Act ivities), Section 9.2(Adverse Events) ,
and Sect ion 9.4(Safety) of this protocol.
8.3. Lost to Follow -Up
A study parti cipant willbe considered lost to follo w-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.  Si te personnel are expected to 
make diligent attempts to contact study part icipant s who fail to return for a scheduled visit or 
were otherwise unable to be fo llowed up by  the si te.
I8H-MC-BDCM Clinical Protocol Page 47
LY32095909.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the l aboratory  tests that will be performed for this study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of rece ipt of confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Assessments
The primary  efficacy  measure is HbA1c change from baseline to Week 32.
9.1.2. Secondary Efficacy Assessments
HbA1c change fro m baseline to Week 12
Fasting glucose change fro m baseline to Weeks 12 and 32
Insulin dose change fro m baseline to week 12 and 32
9.1.3. Appropriateness of Assessments
Efficacy and safet y assessments included in this study  are generally  regarded as reliable and 
accurate with respect to the efficacy and safet y assessments in individuals and populat ions with 
T2DM .
9.1.4. Body Weight
Body  weight will be m easured at prespecified t ime points (see Schedule o f Activities, Secti on 2).  
Study  parti cipant s will be weighed in a light hospital gown or standard clinical research site
scrubs at approximately  the same t ime in the morning after an overnight fast and after evacuat ion 
of bowel  and bladder contents, if possible.  Weight will be measured once at screening 
(non-fasting) and recorded i n the source document and eCRF.  At lead-
inand rando mizat ion 
(Visit 2 and Visit 3, respectively ) and all  subsequent visits indicated in the Schedule o f Activities
(Secti on 2),weight will be measured twice, with the study  parti cipant stepping off the scale 
between m easurements.  Both weight measurements will be recorded in the source document and 
the eCRF.  Calibrated (wi thin 6 m onths prior to study  start) scales should be used. The same 
scale should be used for all weight measurements throughout the study  and shoul d not be m oved 
during the conduct of the study .
I8H-MC-BDCM Clinical Protocol Page 48
LY32095909.2. Adverse Events
Invest igators are responsible for mo nitoring the safety  of study  parti cipant s who have entered 
this study  and f or alerting Lilly or its designee to any event that seems unusual, even if theevent 
may be considered an unant icipated benefit to the study  participant .
The invest igator is responsible for the appropriate medical care of study  parti cipant s during the 
study .
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate h ealth care opti on, 
AEs that are serious or otherwise medically important, considered related to the IP or the study , 
or that caused the study  parti cipant to discontinue the IP before complet ing the study.  The study  
participant shoul d be fo llowed unt il the event resolves, stabilizes with appropriate diagnostic 
evaluat ion, or is reasonably  explained.  The frequency of follow -up evaluat ions of the AE is left 
to the di scret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each study  parti cipant ’s preexist ing condit ions, including clinically significant signs and 
symptoms of the disease under treatment in the study .  In addi tion, si te personnel  will record any  
change in the condit ion(s) and any new condit ions as AEs. Invest igators should record their 
assessment of the potential relatedness of each AE to protocol pr ocedure, IP, via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to IP, study  device, or a study  procedure, taking into account the disease, 
concomitant treatment or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a study  parti cipant ’s IP i s discont inued as a result of an AE, study site personnel must report 
this to Lilly or i ts desi gnee via eCRF, clarifying i f possible, the circumstances leading to any  
dosage modificat ions, or discont inuat ions of treatment. 
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged instudy  parti cipant hosp italizatio n
I8H-MC-BDCM Clinical Protocol Page 49
LY3209590a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospitali zation but m ay jeopardi ze the study  parti cipant or may require 
intervent ion to prevent one of the other outcomes listed in the definit ion above.   
Examples of such medical events include allergic bronchospasm requiring 
intensive treatm ent in an eme rgency  room  or at home, blood dyscrasias or 
convulsio ns that do not result in in study  parti cipant hospi talizat ion, or the 
development of drug dependency  or drug abuse.
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the study  parti cipant has signed the ICF 
and has received IP.  However, if an SAE occurs after signing the ICF, but prior to receiving IP, 
the SAE should be reported to the sponsor as per SAE reporting requirements and timelines (see 
Secti on9.2) if it is considered reasonably possibly related to study procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.Study  parti cipant s with a serious hepatic adverse event should have addit ional data 
collected using the eCRF.
Pregnancy ( during maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements ,any pregnancy  should be reported following the 
SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively  seek AEs or SAEs in subjects once they  have 
discontinued and/or completed the study  (the study participant disposi tion CRF has been 
completed).  However, if the investigator learns of any SAE, including a death, at any  time after 
a subject has been discharged fro m the study , and he/she considers the event reasonably possibly  
related to the study  treatm ent or study  parti cipat ion, the invest igator must prompt ly notify Lilly.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions
Susp ected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  United States 21 CFR 
312.32 and European Unio n Clinical Trial Directive 2001/20/EC andthe associ ated detailed 
guidances or nati onal regulatory  requi rements in parti cipat ing countries require the reporting of 
SUSARs.  Lilly has procedures that will be fo llowed for the ident ificat ion,recording and 
expedited reporting of SUSARs that are cons istent with global regulat ions and the associated 
detailed guidances.
I8H-MC-BDCM Clinical Protocol Page 50
LY32095909.2.2. Adverse Events of Special Interest
9.2.2.1. Hypoglycemia
Study  parti cipant s will co llect informat ion on epi sodes of hypoglycemia starting fro m Visit 2 
until the last study visit (Visit 801 or ET visit).  For that purpose, study participant s will be 
trained about signs and symptoms o f hypoglycemia, how to treat hy poglycemia, and how to 
collect in study  diary  appropri ate information for each episode of hypoglycemia according to the 
Schedule of Act ivities (Section 2).  Si te personnel will enter this information into the eCRF at 
visits indicated in the Schedule of Act ivities (Section 2).
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an episode considere d to be rel ated to hy poglycemia (the PG val ues in this sect ion refer to values 
determined by a lab oratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  
Medicine plasma -
equivalent glucose meters and strips) ( American Diabetes Associat ion2005):
Documented symptomatic hypoglycemia is defined as any time a study  
participant feels that h e/she is experiencing symptoms and/or signs associat ed 
with hypoglycemia, and has a PG level o f ≤70 m g/dL (≤3.9 mmo l/L).
Asymptomatic hypoglycemia is defined as any event not accompanied by t ypical 
symptoms of hypoglycemia but with a measured PG ≤70 mg/dL (≤3.9 mmo l/L).
Probable symptomatic hypoglycemia is defined as an event during which 
symptoms of hypoglycemia are not accompanied by a PG determinat ion (but that 
was presumably caused by a PG concentration ≤70 m g/dL [≤3.9 mmo l/L]).
Severe hypoglycemia is defined as an episode requiring the assistance o f another 
person to actively administer carbohy drate, gl ucagon, or other resuscitative 
actions.  These epi sodes may  be associ ated wi th sufficient neuroglycopenia to 
induce seizure or coma.  Plasma glucose measurements may not be available 
during such an event, but neurological recovery attributable to the restoration of 
PG to normal is considered sufficient evidence that the event was induced by a 
low PG concentrati on.
Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs 
between bedt ime and waking.
Total hypoglycemia is defined as any event meet ing the criteria for documented 
symptom atic hypoglycemia, asymptomat ic hypoglycemia, or probable 
symptom atic hypoglycemia
Cases of relat ive hypogl ycemia are defined as symptomat ic events during which 
the person reports any  of the ty pical symptom s of hypoglycemia and interprets 
those as indicat ive of hypoglycemia, but a measured PG concentration >70 mg/dL 
(>3.9 mmo l/L) is collected.
For addi tional analysis, hypoglycemia defined as glucose <54 mg/dL (<3.0 mmo l/L) will also be 
considered.
I8H-MC-BDCM Clinical Protocol Page 51
LY3209590If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious on the AE
eCRF and reported to Lilly as an SAE.
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly 
categori zed, the effect of the intervention be assessed, and the frequency and durati on of 
hypoglycemia be evaluated.  The role of dietary  changes and physical exercise (or any  other 
contributing factor) in the development of an event should be established.  The study  parti cipant
shoul d receive addi tional educati on, if deemed appropri ate.  Management of increased risk of 
hypoglycemia is described in Sect ion 7.8.2.2 .
9.2.2.2. Allergic/Hypersensitivity Reactions
All allergic or hy persensi tivity react ions, including injection site react ions,will be reported by  
the invest igator as either AEs or, if any serious criterion is met, as SAEs.  Additional data, such 
as type of react ion and treatment received, will be collected on any  AEs or SAEs that the 
investigator deems related to IPvia a n eCRF created for this purpos e.  IPshould be temporarily 
interrupted in any individual suspected of having a severe or serious allergic reaction to IP
(Secti on8.1.2 ).  IPmaybe restarted when/if it is safe to do so, in the opinio n of the invest igator.  
If IPis permanently discont inued, see Section8.1.1 for procedures required in this situation .
9.2.3. Adverse Event Monitoring with a Systematic Questionnaire
Not applicable. 
9.2.4. Complaint Handling
Lilly co llects product complaints on invest igational pr oducts and drug delivery  system s used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Study  parti cipant swill be instructed to contact the investigator as soon as possible if he or she 
has a com plaint or probl em with the IPso that the situation can be assessed .
9.2.4.1. Device Complaint Handling
Any CGM device co mplaint shoul d be reported via the manufacturer’s instructions for device 
complaints.  A 24 -hour toll -free numbe r will  be provi ded to the invest igative site personnel in the 
event that either personnel or study  parti cipant s have quest ions regarding the device.
9.3. Treatment of Overdose
Study  drug overdose (more than the specified number of injections) will be reported as an AE. In 
the event of an overdose, refer to the IB for LY3209590 and/or product label. 
9.4. Safety
9.4.1. Cardiovascular Events
Deaths and nonfatal CV AEs will be adjudicated by a committee of physicians external to Lilly 
with cardi ology expertis e.  The nonfatal  CV AEs to be adjudicated include:  myocardial  
infarction ; hospi talizat ion for unstable angina; hospitalizat ion for heart failure; coronary  
I8H-MC-BDCM Clinical Protocol Page 52
LY3209590intervent ions (such as coronary  artery  bypass graft or percutaneous coronary  intervent ion); and 
cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic 
attack.
9.4.2. Electrocardiograms
For each study  participant , 12-lead di gital ECGs , as well as single and triplicate safet y ECGs,
will be co llected according to the Schedule of Activit ies (Secti on 2).  Study  parti cipant s must be 
supine for approximately  5 to 10 minutes before ECG collect ion and rem ain supine but awake 
during ECG collect ion.ECGs will be performed prior to collect ion of any  blood sam ples.
ECGs will be interpreted by  a qualified physician ( the invest igator or qualified designee) at the 
site as soon as possible after the time of ECG collection, and ideall y while the study  parti cipant
is still present, to determine whether the study  participant meets entry  criteria at the rel evant 
visit(s) and for immediate study  parti cipant management should any clinically relevant findings 
be ident ified.
Digital ECGs will be electronically transmitted to a central ECG laboratory  designated by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  details) then store the ECGs in a database.  At a future time, the s tored 
ECG data may be overread at the central ECG laboratory  for further eval uation of  machine -read 
measurements or to meet regulatory  requi rements.
The m achine -read ECG intervals and heart rate may  be used for data analysis and report writing 
purposes unl ess an overread of the ECGs is conducted prior to complet ion of the final study  
report (i n which case the overread data would be used).
9.4.3. Vital Signs
Sitting blood pressure ( BP)and pulse rate will be measured using autom ated el ectronic 
sphygmo mano meter according to the Schedule o f Activities (Secti on 2).Vital sign 
measurements should be taken before obtaining an ECG tracing and before collect ion of blood 
samples for laboratory  testing, at vi sits where required (see Schedule of Act ivities,Secti on 2). 
The parti cipant shoul d be required to sit quietly for 5 minutes before vital sign m easurements are 
taken. An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be 
used to ensure the accuracy  of BP m easurements.  The arm used for the BP measurement should 
be supported at heart level. Blood pressure shoul d be m easured consistent ly using the same arm 
through out the study .  
For each parameter (pulse rate, sy stolic BP, and diastolic BP) , 
3measurements will be taken using the same arm ; the recordings should be taken at least 
1minute apart , and e ach measurement of sitt ing pulse rate and BP willbe recorded in the eCRF.
9.4.4. Self-monitoring of Blood Glucose Using CGM
A CGM system will be used in this study  for self-measurement of plasma gl ucose equivalents . 
This system readings will be used for the purpose of monitoring study  parti cipant safet y 
(hypo glycemia) and values shown by the system will be used for SMBG documentation .  The 
system  will proacti vely warn study  parti cipant s of low blood glucose values. Study  parti cipant s
I8H-MC-BDCM Clinical Protocol Page 53
LY3209590shoul d record all hypoglycemia related values read on the CGM device in the study diaries
provi ded.  Study  parti cipant swith missing SMBG values may need to be retrained on the 
importance of SMBG mo nitoring.
Study  parti cipant swillbe instructed to take a pre -breakfast (fasting) SMBG reading every  
morning and 4 -point SMBG m easurem ents (consisting of fasting, pre -lunch, pre -dinner, and 
bedtime blood glucose measurements) once weekly throughout the study, and to record all 
resul ts in di aries. Study  parti cipant s will also measure FBG as needed to evaluate symptoms of 
hypoglycemia.
Study participant swillbe instructed to perform 6-point SMBG profiles over a 24 -hour period on 
2nonconsecut ive days during the 7-day period prior to visits indicated in the Schedule o f 
Activities (Section 2).  The 6-point profile consists of pre -meal and 2 - hour postprandial SMBG 
measurements for the morning, midday, and evening meals in 1 day .  Pre -meal measurements 
shoul d be taken before the study participant begins eating the meal.  Study  parti cipant sshoul d 
record their glucose measurements in their study  diari es which are considered source documents 
and are to be returned to the invest igator at each study visit.  Values fro m the 6-point SMBG 
profiles will be transferred from the diaries and recorded on the eCRFs. 
9.4.5. Continuous Glucose Monitoring
A CGM system will be provided to participat ing investigative sites.  Study
-specific training will 
be provided to invest igative site personnel and study  participant s.  The allowed range of the 
instrum ent recording is from 40 mg/dL to 400 mg/dL (2.2 mmo l/L to 22.2 mmo l/L) in the 
interstitial fluid (Gross et al. 2000).  The results of the continuous monitoring will be unblinded 
to study  parti cipant s and inve stigative site personnel and will be downloaded for transfer to Lilly 
or desi gnee.
The study  parti cipant s will be thoroughly trained on sensor insert ion and usage ,and CGM 
data/alarm interpretation during the rando mizat ion visit. Study  partici pants should self -insert the 
first sensor at Visit 3and init iate the CGM system  under supervisio n of the trained si te personnel. 
Thereafter ,study part icipant s will be provided wit h the necessary  CGM supplies and will 
self-insert new sensors when alerted by  the system.
The CGM device and sensor will mo nitor study participant glucose levels.  Study  parti cipant s 
will be unblinded to the real t ime CGM monitor readouts and alarms ,so corrective action can be 
taken at the site regarding hypoglycemia prevention.
Ifproblems occur with the CGM monitor or sensor, another sensor may  be inserted or a 
replacement m onitoring instrum ent m ay be used, as l ong as the CGM procedures and the 
subsequent visits cont inue to fall wit hin the allowable time frames.  A sensor or monit oring 
instrum ent provi ded specifically  for thi s study  must be used when replacing another sensor or 
CGM m onitor.
I8H-MC-BDCM Clinical Protocol Page 54
LY32095909.4.6. Laboratory Tests
For each study  participant , laboratory  tests detailed in ( Appendix 2 ) shoul d be conducted 
according to the Schedule of Act ivities (Secti on 2). 
With the exception o f laboratory  test resul ts that may  unblind the study , Lilly or its desi gnee will 
provi de the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor i s used for the clinical trial.
Any clinically  significant findings from laboratory tests that result in a diagnosis ,and that occur 
after the study  parti cipant receives the first dose of IP shoul d be reported to Lilly  or its designee 
as an AE via eCRF .
9.4.7. Immunogenicity Assessments
Venous blood samples of approximately 10 mL will be co llected to determine ant ibody  
producti on against LY3209590 as specified in the Schedule of Act ivities (Section 2).  To 
interpret the resul ts of immunogenicit y, a PKsample will be co llected at the same t ime points to 
determine the concentrations o f LY3209590. All samples for immunogenicit y should be taken 
predose when applicable and possible. In the event of drug hypersensit ivity react ions 
(immediate or non -immediate) , 
additional blood samples will be co llected foranti-drug 
antibodies (ADA) , PK and exploratory  hypersensitivit y analyses at the following time points, as 
close as possible to the onset of the event , at the resolut ion of the event, and 30 (±3) days
following the event . Exploratory  hypersensi tivity samples may  be analyzed for m arkers of 
basophil/mast cell act ivation (e.g., try ptase), immune com plex formation (e.g., C3 levels) and 
cytokine release (e.g., IL -6) as appropriate for the clinical presentation. Instructions for the 
collect ion and handling of blood samples will be provided by the sponsor. The actual date and 
time (24-hour clock time) of each sampling will be recorded.
Immunogenicit y will be assessed by  a validated assay  designed to detect ADA in the presence of 
LY3209590 at a l aboratory  approved by  the sponsor. For the detection of anti -LY3209590 
antibodies ,study  parti cipant sera samples will be analyzed using a 3-tiered approach.  All 
samples will be assessed in Tier 1 (screening) for possible presence of ADA.  Samples found to 
produce a si gnal above or equal  to the screening cut point wil l be assessed in Tier 2 to confirm 
specificit y to LY3 209590 (confirmat ion).  Any samples confirmed as specific for LY3 209590
will be reported as “detected”.  All samples below the screening cut point in Tier 1 or not 
confirmed in Tier 2 will be reported as “not detected”.  All “detected” samples in Tier 2 will be 
assesse
d in Tier 3 (ti ter assessment) .In vivo laboratory  indicators for glycemic control ( blood 
glucose and HbA1c) will be utilized to detect a potent ial neutralizing effect of ADA against 
LY3209 590.
Treatment -emergen t  anti drug ant ibodies ( TE-ADA) are defined in Sect ion10.3.6 . A risk-based 
approach will be used to monitor study participant s who develop TE
-ADA after treatm ent wi th 
LY3209590. Clinically significant TE -ADA will be defined as any TE -ADA at the fo llow-up 
visit with:
- A titer ≥ 1:640 or increasing ADA titerat follow-up visi t.
-An associ ation of TE-ADA wit h moderate to severe inject ion site reaction
I8H-MC-BDCM Clinical Protocol Page 55
LY3209590Study  parti cipant s who have clinically significant TE- ADA will be fo llowed wi th ADA testing 
(every 3 months for up to 1 y ear after dose) until the titer reaches a plateau/decreases (if 
increasing) or remains the same/decreases (if high). A PK sample will cont inue to be collected 
at each time po int at the invest igator’s discretion.
Samples will  be retained for a m aximum  of 15 y ears after the last study part icipant visit, or for a 
shorter period if local regulat ions and Ethical Review Boards (ERBs) allow, at a facilit y selected 
by the sponsor.  The duration allows the sponsor to respo nd to future regulatory requests related 
to the LY3209590 .  Any samples remaining after 15 years will be destroyed.
9.4.8. Other Tests
Not applicable.
9.4.9. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods. Lilly will also review SAEs wit hin the time frames mandated by  com pany  procedures.  
The Lilly CRP will, as appropriate, consult with the functionally independent Global Study  
participant Safet y therapeutic area physician or clinical scient ist.
9.4.9.1. Hepatic Safety Monitoring
If a study participant experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL 
≥2X ULN, liver testing ( Appendix 4 )shoul d be repeated wi thin 3 to5 day s including ALT, AST, 
ALP, TBL, direct bilirubin , gamma- glutamyl  transferase (GGT) ,and creatine kinase to confirm 
the abnormalit y and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worse ns, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultation wit h the study  medical mo nitor.Monitoring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels.
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1 or more of the fo llowing condi tions 
occur: 
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated serum TBL to ≥ 2X ULN (except for cases of kno wn Gilbert’s 
syndro me)
elevation of serum  ALPto ≥2X ULN on 2 or more consecutive blood tests
study  participant discontinued from treatment due to a hepatic event or 
abnorm ality of liver tests
hepatic event considered to be a nSAE .
I8H-MC-BDCM Clinical Protocol Page 56
LY32095909.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities(Secti on 2),venous blood samples 
will be collected to determine the plasma concentrations o f LY3209590.   After Visit 3, PK 
samples can be taken at any t imeduring the visit.
Instructi ons for the collect ion and handling of blood samples will be provided by the sponsor.   
The actual  date and time (24 -hour clock time) of each sampli ng will be recorded.
All the samples will be analyzed at a laboratory  by the Sponsor, and stored at a facilit y 
designated by  the Sponsor.
Plasma concentrations o f LY3209590 will ut ilize a validated enzyme -linked immunosorbent 
assay method.
Bioanaly tical samples collected to m easure IP concentration will be retained for a maximum of 
1year fo llowing last study  parti cipant visit for the study.
9.6. Pharmacodynamics
In addit ion to PD parameters already discussed in the efficacy and safet y sections,fasting plasma 
free fatty  acids and fast ing triglycerides will be evaluated as PD bio markers of lipo lysis, which is 
a sensit ive measure of peripheral insulin act ivity.
9.7. Pharmacogenomics
9.7.1. Whole Blood Sample sfor Pharmacogenetic Research
A whole blood sam ple will  be collected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Secti on2)where local regulat ions allow .
All samples will be coded with the study  parti cipant number.  These samples and any data 
generated can be linked back to the study  parti cipant only by  the invest igator site personnel.
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15years 
after the l ast study  parti cipant visit for the study , or f or a shorter peri od if local regulat ions and/or 
ERBs /invest igational review boards impose shorter time limits.  This retention period enables 
use of new techno logies, response to regulatory  questi ons, and invest igation of variable response 
that may  not be observed unt il later in the devel opment of LY3209590 or after LY3209590 
beco mes commercially available .
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, and candidate gene studies.  Regardless of 
techno logy utilized ,genoty ping data generated will be used only for the specific research scope 
described in this sect ion.
I8H-MC-BDCM Clinical Protocol Page 57
LY32095909.8. Biomarkers
Biomarker research is performed to address questions of relevance to drug di sposi tion, target 
engagement, PD, mechanism of act ion, variabilit y of study  parti cipant response (including 
safet y), and clinical outcome.  Sample collect ion is incorporated into clinical studies to enable 
examinat ion of these questions through measurement of bi omol ecules including DNA, RNA, 
proteins, lipids, and other cellular elements.
Serum  and plasma samples for non -pharmacogenetic bio marker research will be co llected at the 
times specified in the Schedule of Act ivities (Section 2)where local regulat ions allow.
Samples will  be used for research on the drug target, disease process, variable response to 
LY3209590 pathways associated with T2DM, mechanisms of action of LY3209590 and/or 
research methods
,or in validat ing diagnost ic tools or assay(s) related to T2DM.
All samples will be coded with the study  parti cipant number.  These samples and any data 
generated can be linked back to the study  parti cipant only by the invest igator site personnel.
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15 years 
after the l ast study  parti cipant visit for the study , or f or a shorter peri od if local regulat ions and 
ERBs impose sh orter time limit s.  Thi s retenti on peri od enables use of new techno logies, 
response to regulatory  quest ions, and invest igation of variable response that may not be observed 
until later in the devel opment of LY3209590 or after LY3209590 beco me(s) commercial ly 
available .
9.9. Health Economics
No heal th economic outcomes are planned.
I8H-MC-BDCM Clinical Protocol Page 58
LY320959010.Statistical Considerations
10.1. Sample Size Determination
Approximately  375 study  parti cipant s will be randomized in a 1:1:1 ratio to LY3209590 in one 
of two dosing algorithms or insulin degludec treatment arms, assuming a 20% dropout rate 
resul ting in approximately  
300 total com pleter sat 32weeks ( 100 completers pertreatm ent arm ). 
The sample size was calculated based on the st atistical power for the primary  and liver safet y
endpo ints.
The 300 completers will provide 90% stati stical power to demonstrate the noninferiorit y 
of the pool ed LY3209590 arms versus insulin degludec for the change in HbA1c from 
baseline to 32weeks (ass uming non
-inferiorit y margin is 0.4%, the SD is 1.1% and true
mean difference is 0%) using two sided t -test at alpha = 0.1 .
10.2. Anal ysisSets
For purposes of analysis, the following populat ions and analysis sets are defined:
Population and Analysis Set Description
Enrolled All study participants who sign informed consent
All randomized study 
participant sAll study participant s who are randomly assigned a treatment arm
Efficacy analysis set (EAS) Data for all randomized study participant s who received at least one dose of 
study med ication, excluding data after usi ng rescue medication or stopping 
study med ication (last dose date + x xdays). In the event of a treatment error, 
participants will be analyzed according to the treatment they actually received.
Full analysis set (FAS) Data for all randomized study participant s, regardless of titration, stop of study 
medication , or rescue.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee.  Any change to 
the stati stical met hods described in the protocol will require an amendment only if it changes a 
principal feature of the protocol.  Any other change to the statist ical analyses and the j ustificat ion 
for the change will be described in the statist ical analysis plan (SAP) and/or clinical study  report.  
Addit ional exploratory  analyses of the data may  be perform ed as deemed appropriate.  Analyses 
will be fully detailed in the SAP.
Statistical analyses (including the primary analysis) will be conducted on the efficacy analysis
setpopulat ion.  Safety analyses will be performed on the full analysis set .
No adj ustments for multiplicity will be performed.
All tests of treatment effects will be conducted at a two-sided al pha level of 0.1 and/or two-sided 
90% confidence interval, un less otherwise stated.
I8H-MC-BDCM Clinical Protocol Page 59
LY3209590The baseline value used for the analyses will be the last scheduled baseline value obtained for 
each study  parti cipant prior to randomizat ion.ALT, AST, and GGT will be average of 
3assessments as baseline .
The analysis of the main secondary  efficacy endpoint and possibly  other Bay esian analyses may
be co mputed using Fixed and Adapt ive Clinical Trial Simulator software.  Remaining summaries 
and analyses will be performed using the SAS Sy stem .
10.3.2. Treatment Group Comparability
10.3.2.1. Study P articipant Disposition
Intention -to-treat populat ion will be used for this analysis.  All study  parti cipant s who 
discontinue the study  will be i dentified, and the extent of their participation in the study will be 
reported.  If known, a reason for their discont inuat ion will be given.  The primary reasons for 
discontinuat ion will  be listed and will be summarized by treatment.  The di scont inuat ion due to 
AEwill be summarized by  adverse event and treatment. The percentage of study  parti cipant s 
discontinuing fro m each treatment will be compared using the Fisher’s exact test.
10.3.2.2. Study Participant Characteristics
Intention -to-treat populat ion will be used for this analysis. Dem ographic and baseline 
characterist ics will be summarized by treatment group.  Categorical variables will be 
summarized by  frequencies and percentages.  For categorical variables, comparisons between 
treatm ent groups will be assessed using a Pearson chi-square test.  Continuous variables will be 
summarized by  mean and SD.  For continuous variables, comparisons between the treatment 
groups will be performed using a 1 -way analysis of variance wit h treatment as the fixed effect.
10.3.2.3. Concomitant Therapy
Intention -to-treat populat ion will be used for this analysis. Listings and summary o f conco mitant 
therapi es will  be provi ded by treatm ent group .
10.3.2.4. Treatment Compliance
Treatment compliance will be listed using all randomized study  parti cipant s and summarized 
using the modified i ntention-to-treat population.  For a given study  parti cipant , overall 
compliance for treatm ent peri od is defined as, not missing 2 or more consec utive doses of the 
assigned treatment ,or,missing 4 or more at any  point in the study .  Study  parti cipant s who miss 
4 or m ore doses at any  point duri ng the study  will not be included in the efficacy analysis.
Adherence to the dosing algorithm isrequi redfrom Visit 3 (Rando mizat ion) up to Visit 21
(Week 32, inclusive), although the last scheduled opportunit y for dose adj ustment will occur at
Week 31. Adherence to the dosing algorithm w ill beassessed based on the number and 
percentage of investigator -reported prescribed dos es that d onot fo llow the inv estigator -
calculated al gorithm dose, which represent intent ional deviat ion from the algorithm, and the 
number and percentage of investigator -calculated doses that are not equal to the sponsor -
calculated al gorithm doses.
I8H-MC-BDCM Clinical Protocol Page 60
LY320959010.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
The primary  efficacy  outcome i s HbA1c change from baseline to Week 32for LY arms .  The 
mixed -effect m odel repeated m easures (MMRM) wi th BMI str ata, treatment, visit, SU(Y/N) ,
and treatment -by-visit interaction as fixed effects, HbA1c baseline as a covariate will be used for 
the analysis. The wi thin-study  parti cipant correlation will be modelled through a variance -
covari ance structure .  The depe ndent variable will be the post- baseline change fro m baseline 
values.  The unstructured covariance matrix will be selected init ially.  There will be no explicit 
missing data imputation as the missing values are handled implicit ly by  the MMRM model. 
10.3.3.2. Secondary Analyses
The secondary  analysis will be perform ed on the efficacy  analysis set. The main secondary
efficacy  analysis aims to compare LY versus Insulin Degludec with regarding to HbA1c change 
from baseline at Week 12 and 32.The estimand o f interest is the treatm ent differences in HbA1c 
at 12 and 32 weeks while the study  parti cipants are on study  treatm ent.  The efficacy analysis set 
(EAS) will be used to calculate the mean difference between treatments.  Similar MMRM m odel 
will be used for the mai n secondary  analysis. The least-squares (LS) m ean differences and the 
standard errors from each imputed sample will be calculated based on the above model, and the 
final est imation for the means, standard errors, 90% confidence intervals, and p -values will be 
reported.
A supplementary  analysis will be conducted to evaluate the “treatment policy” est imand, which 
is defined as the treatment differences in HbA1c at 32 weeks with the rando mized treatment 
based on FAS.  The estimator is defined as the mean diffe rence between treatm ents based on 
FAS.  The missing values will be imputed using mult iple imputations. The similar MMRM 
model will be performed on imputed data and inferences will be drawn based on the framework 
of multiple imputati ons (Rubin, 1987). 
In addition to the main secondary efficacy  analysis of HbA1c, the fo llowing secondary  efficacy  
outcom es will  be analyzed:
Body  weight and c
hange from baseline to 12 and 32 weeks
Fasting blood glucose and c hange from baseline at 12 and 32weeks
Theanalys es of the HbA1c change, mean weight change, fasting blood glucose change and 
SMBG change from baseline will be conducted through MMRM similar to that of the primary  
efficacy  outcom e.The corresponding baseline will be used in the model instead of the baseline 
HbA1c levels.  The MMRM model will also include a term for the HbA1c stratification group.
The treatment p -value will be used as evidence of difference between LY3209590 and insulin 
degludec , while the com parison of LS means versus insulin degludec (unadj usted for m ultiple 
comparisons) and its 9 0% confidence interval will provide magnitude and significance of this 
difference.
I8H-MC-BDCM Clinical Protocol Page 61
LY320959010.3.3.3. Exploratory Analyses
LY3209590 concentration data will be analyzed using standard nonlinear mixed -effects 
modeling implemented on the NONMEM software.  The relationships between LY3209590 dose
and/or concentration and efficacy, tolerabilit y, and safet y endpoints will be characterized , such 
as fast ing glucose, SMBG , HbA1c, hypoglycemia, body  weight, bl ood pressure, pul se rate, and 
corrected QT interval ( QTc).
Addit ionally , the impact of intrinsic and extrinsic study  parti cipant factors such as age, weight, 
gender and renal funct ion on PK and/or PD parameters may  be examined as needed.  If ADA
titers aredetected from immunogenicit y testing, then the impact of immunogenicit y titers on 
LY3209590 PK or any  relevant PD parameters will  also be examined.
10.3.4. Safety Analyses
The FAS will be used for safet y analyses.  Both the overall and the pairwise comparisons of each 
LY3209590 armversus insulin degludec will be reported for these safet y analyses.
Safety measures include liver bio markers (ALT), hypoglycemia, vital signs (BP and pulse rate) , 
body  weight, TEAEs (including SAEs and AEs o f special interest), laboratory  measures 
(including ant i-LY3209590 antibodies), and ECGs. Summary statist ics will be presented by  
treatm ent for the safet y measures.
The summary statistics for continuous variables wil l be sam ple size, m ean, SD, median, 
minimum, and maximum.
The summary statistics for categorical variables will be sample size, frequency, and percentage.
Exposure to each therapy  during the treatm ent period of the study  will be calculated for each 
study  participant and summarized by treatment group.
In addit ion, the fo llowing safet y outcom es will be analyzed on the efficacy analysis set
popul ation:
ALT c hange fro m baseline to 12 and 32weeks
The change from baseline of ALT will be analyzed using MMRM m odel. In addit ion, Bayesian
model will be used to conduct the same analysis. The corresponding baseline will be used in the 
model instead of the baseline HbA1c levels.  The MMRM model will also include a term for the 
HbA1c stratificat ion group.
Addit ional analyses, such as concentration -safet y laboratory plots, m ay be perform ed,if 
warranted upon review of the data.
10.3.4.1. Adverse Events
Adverse Events will be listed by study  partici pant, actual term, preferred term, severit y, and 
relationship to the treatment.  AEs will be summarized as TEAEs (defined as events that are 
newly reported after randomizat ion or reported to worsen in severit y from baseline).  The 
incidence of study  parti cipant s with at least 1 TEAE and the incidence of TEAEs by preferred 
term and system organ class will be presented by  treatm ent group.  The frequency  and 
I8H-MC-BDCM Clinical Protocol Page 62
LY3209590percentage of TEAEs will be presented.  The incidence of study  parti cipant s with at least 
1TEAE assessed as possibly related to the invest igational drug will be summarized by treatment 
group, in addit ion to the incidence of these possibly related TEAEs by preferred term.  In 
addition, a summary  of TEAEs by  severi ty will be presented descri pt
ively by treatment group.
Reported and adjudicated CVAEs will be listed by study  parti cipant , and if there are a sufficient 
number of cases they  may be summarized by  treatment group.
All SAEs will be listed by  study  participant .  If a sufficient number of SAEs are reported, 
incidence summaries similar to incidence o f TEAEs will be included.
Discontinua tions due to AE and TEAEs will be listed by  study  parti cipant and summarized by 
treatm ent group.
10.3.4.2. Vital Signs
Descript ive statistics for the actual measurements and changes from baseline for systolic and 
diastolic blood pressure and pulserate will be presented by  treatm ent arm  and visi t.  
Corresponding figures may be presented.
Vital signs will  be analyzed using a similar MMRM -based model .
10.3.4.3. Hypoglycemia Episodes
The rate and incidence analyses will be analyzed. Details will be provided in the SAP. Statistical 
analysis will be performed for overall total hypoglycemia, documented symptomat ic 
hypoglycemia and nocturnal hypoglycemia. List ing of hypoglycemic episodes and severe 
hypoglycemic episodes will be presented by  visit for each study  participant. If a sufficient 
number of severe hypoglycemic episodes are reported, then incidence summaries and analysis 
similar to incidence of hypoglycemic episodes will be included. 
10.3.4.4. Laboratory Measures
Summary  statistics will be provided for laboratory meas ures, by  treatm ent group and by  visit.
A listing of laboratory  measurements for individual study  parti cipant s will be presented by visit.  
An addit ional listing will be presented for all laboratory measurements that are outside the 
norm al range.
Descript ive statistics for the laboratory  analyses will  be presented by  treatm ent group and visit, 
including safet y off-treatm ent visi ts.
Laboratory  analyses wi th categori cal responses will be summarized by  visit and treatment group 
using frequency  and percentage.
The maximum/minimum post- baseline observation (as applicable for a laboratory ) will be 
compared to the baseline observat ion by examining the proportion of study  parti cipant s whose 
test val ues are wi thin and outsi de the reference ranges.
I8H-MC-BDCM Clinical Protocol Page 63
LY320959010.3.4.5. Electrocardiograms
Alisting of the individual and averaged ECG measurements, by  study  parti cipant , will be 
produced.  This will include the time elapsed between the onset of ventricular depo larization and 
the end of ventricular repolarizat ion (QT) corrected values described below.
Descript ive statistics for the abso lute measurements, outliers, and changes from baseline for 
selected ECG parameters will be presented by treatment arm.  These include the ECG heart rate, 
and the fo llowing intervals: QT and QT corrected for heart rate using Fridericia’s formula 
(QTcF).
In addit ion, LY3209590 concentration -response analysis o f QTcF results will be performed as 
well as a categorical analys is of abso lute and change fro m baseline QTc intervals. Any 
additional ECG analyses will  be deta iled in the SAP.
10.3.4.6. Adverse Events of Special Interest
Hypoglycemia, m ajor adverse cardi ovascular events, and inject ion site reaction are defined as 
AESIs.
Descript ive statistics for the AESIs will be presented by treatment group and visit.  Continuous 
respon ses will be summarized using sample size, mean, SD, median, minimum, and maximum, 
while categorical responses will be summarized using frequencies and percentages.
If necessary, c ontinuous AESIs will be analyzed using a similar MMRM -based model.
Categori cal AESIs will be analyzed using a logist ic regression analysis wit h fixed effects of 
treatm ent, and HbA1c strata.
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
LY3209590 concentration data will be analyzed using a populat ion PK approach via nonlinear 
mixed -effec ts modeling wi th the NONMEM software. The relationships between LY3209590
and/or concentration and efficacy, tolerabilit y, and safet y as well as bio marker endpo ints will be 
characterized if exploratory  analyses of the PD data warrant further PK/PD analyses upon 
review. Such analyses may include, but are not necessarily limited to, gl ucose, HbA1c, QTc, 
hypoglycemia, and vital signs.
In addit ion, if populat ion PK and PK/PD models can be established ,the impact of addit ional 
subject factors ,such as age, weight, gender and renal funct ion on PK and/or PD parameters, may 
be examined . Should ADA be detected from immunogenicit y testing, its impact on LY3209590
PK or any  relevant PD parameters will also be examined.
10.3.6. Evaluation of Immunogenicity
The frequency of ant ibody  formati on to LY3209590 will be determined. Treatment -emergent 
ADA are defined as those with a titer 2 -fold (1 dilution) greater than the minimum required 
dilution if no ADAs were detected at baseline (treatment -induced ADA) or those with a 4 -fold 
(2dilutions) increase in t iter compared to baseline if ADAs were detected at baseline (treatment -
boosted ADA). For the TE ADA+ study  parti cipant s, the di stributi on of  maximum  titers will  be 
described. 
I8H-MC-BDCM Clinical Protocol Page 64
LY3209590The rel ationship between the presence of ant ibodies, antibody t iters, and clinical parameters (for 
example, AEs, efficacy meas ures) m ay be assessed.
10.3.7. Other Analyses
Detail edanalysis plan for CGM will be documented in SAP.
10.3.7.1. Health Economics
Not applicable.
10.3.7.2. Subgroup Analyses
Subgroup analyses of important factors, including age, race, ethnicit y, gender, durati on of  
diabetes, baseline HbA1c (<8.5% , ≥8.5%), BMI, and other factors to be specified in the SAP are 
planned for the key  outcom es of HbA1c , insulin dose and incidence and rate of hypoglycemia.
These will be conducted using the analysis of covariance model with strata, tre atment, factor, 
treatm ent-by-factor interaction as fixed effects, and baseline as covariate.
Covari ate analysis o f PK and PK/PD m ay be perf ormed.
Other exploratory  subgroup analyses may  be perform ed as deemed appropriate.
10.3.8. Interim Analyses
Interim analyses havebeen pl anned for this study .  The cancellat ion or addi tion of  interim 
analysis will be determined at any  time during the study  and does not need protocol amendment.
Aninterim analysis o f select safet y, efficacy , and PK data is pl anned when approximat ely 50% 
of study  parti cipant s com plete 6 weeks of treatment.  Results of i nterim analysis might be used 
for adjusting L Y3209590 dosing algori thm.   
A subsequent interim analysis of select safet y, efficacy , and PK data is planned when allstudy  
participant s com plete 12weeks of treatment. Results of interim analysis will be used to design 
subsequent studies.
In addit ion, the study team will perform periodic saf etyreviews during the study  and if safet y 
signals or concerns arise from these reviews , safety datamayneed to be in an unplanned interim 
analysis.
Study  sites will receive informat ion about interim results ONLY if they need to know for the 
safet y of their study  parti cipant s.
I8H-MC-BDCM Clinical Protocol Page 65
LY320959011. References
American Diabetes Associat ion. Defining and reporting hypoglycemia in diabetes: a report from 
the American Diabetes Associat ion Workgroup on Hy poglycemia. Diabetes Care . 
2005;28(5):1245 -1249.
American Diabetes Associat ion. Standards of medical care in diabetes—2016. Diabetes Care . 
2016; 39(suppl  1):S4 -S108.
Blonde L, Brunton SA, Chava P, Dalal M, Zhou R, Mey ers JL, Davis KL, Digenio A. 
Achievement of Goal A1C (<7 %) by  U.S. Pati ents wi th T2DM on Bas al Insulin in Both 
Randomized, Controlled Trials (RCTs) and in Clinical Practice . 
Diabetes. 2014;63(Suppl 1): 
A235. 
Food and Drug Administration (FDA) “Assay  Devel opment and Validat ion for Immunogenicit y 
Testing of Therapeut ic Protein Products: Guidance for Industry ” April, (2016).
Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mast rototaro JJ. 
Perform ance Eval uation of  the MiniMed® Continuous Glucose Monitoring System During 
Patient Home Use. Diabetes Technology &  Therapeutics . 2000;2(1):49 -56.
Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra -long-acting insulin degludec has a 
flat and stable glucose -lowering effect in ty pe 2 diabetes. Diabetes Obes Metab.
2012;14(10):944 -950.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of Hy perglycemia in Ty pe 2 Diabetes, 2015: A 
Patient-Centered Approach: Update to a Posit ion Statement of the American Diabetes 
Associ ation and the European Associat ion for the Study  of Diabetes. Diabetes Care . 
2015; 38(1):140 - 149.
Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study  Investi gators. The Treat -to-
Target Trial: Rando mized addit ion of glargine or hum an NPH insulin to oral therapy  of type 2 
diabetic pat ients. Diabetes Care . 2003;26:3080 –3086.
Rubin DB. Procedure s with nonignorable nonresponse. Multiple Imputation for Nonresponse in 
Surveys .
1987:202-243.
Tresiba® prescribing informat ion [USPI 2015]. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf. Accessed January 
11, 2018.
I8H-MC-BDCM Clinical Protocol Page 66
LY320959012. Appendices
I8H-MC-BDCM Clinical Protocol Page 67
LY3209590Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrug antibodies
AE adverse event:  Any untoward medical occurrence in a study participant or clinical 
investigation subject administered a pharmaceutical product that does not necessarily 
have a causal relationship with this treatment.  An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory find ing), symptom, 
or disease temporally associated with the use of a medicinal (investigational) product, 
whether o r not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALP alkaline phosphate
ALT/SGPT alanine aminotransferase/ serum glutamic pyruvic transaminase
AST/SGOT aspartate aminotransferase/ serum glutamic oxaloacetic transaminase
AUC area under the curve
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the study participant is not, or vice versa, or when the sponsor is aware of 
the treatment but the investigator and/his staff and the study participant are not.
A double -blind study is one in which neither the [study participant /subje ct]nor any  of 
the investigator or sponsor staff who are involved in the treatment or clinical evaluation 
of the subjects are aware of the treatment received .
BMI body mass index
BP blood pressure
CGM continuing glucose monitoring
Com plaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRP clinical research physician : individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR clinical study report
CV cardiovascular
DPP-4 dipeptidy l peptidase -4
I8H-MC-BDCM Clinical Protocol Page 68
LY3209590ECG electrocardiogram
eCRF electronic case report form
Enroll The act of assigning a study participant to a treatment.   Study participant swho are 
enrolled in the trial are those who have been assigned to a treatment.
Enter Study participant s entered into a trial are those who sign the informed consent form 
directly or through their legally acceptable representatives.
ERB Ethics Review Board
ET early  termination
FAS full analy sis set
FBG fasting blood glucose
FBS Fasting bloo d sugar
FPG fasting plasma glucose
GCP good clinical practice
GGT gamma -glutamyl transferase
HbA1c hemoglobin A1c
ICF informed consent form
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
product (IP)Apharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial ,including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IWRS interactive web -response sy stem
LS least squares
LY LY3209590
MAD multiple ascending dose
MMRM mixed-effect model repeated measures
NAFLD non-alcoholic fatty liver disease
OAM oral antihy pergly cemic medication
OTC over the counter
I8H-MC-BDCM Clinical Protocol Page 69
LY3209590PD pharmacodynamic
PG plasma glucose
PK pharmacokinetics
PP per-protocol set : The set of data generated by the subset of study participant swho 
sufficiently complied with the protocol to ensure that these data would be likely to 
exhibit the effects of treatment, according to the underlying scientific model.
QTc corrected QT interval
QTcF QT corrected for heart rate using Fridericia’s formul a
SAD single -ascending dose
SAE serious adverse event
SAP Statistical analysis plan
SC subcutaneous
SD standard deviation
SGLT sodium -glucose cotransporter
SMBG self-monitoring of blood glucose
SMPG self-monitored plasma glucose
SU sulfon ylureas
SUSARs suspected unexpe cted serious adverse reactions
Screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
T2DM type 2 diabetes mellitus
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, which and does not necessarily have to have a causal 
relatio nship with this treatment.
ULN upper limit of normal
I8H-MC-BDCM Clinical Protocol Page 70
LY3209590Appendix 2. Clinical Laboratory  Tests
Hematology a Clinical Chemistry a, b
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Chloride
Mean cell volume Bicarbonate
Mean cell hemoglobin Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase (ALP)
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Gamma -glutamyltransferase (GGT)
Eosinophils Blood urea nitrogen (BUN)
Basophils Creatinine
Platelets Uric acid
Calcium
Urinalysis a, c Phospho rus
Protein Glucose
Nitrite Total protein
Blood Albumin
Urine leukocyte esterase Creatine kinase
Cholesterol
Pregnancy testserum and urine (females only) a, d Triglycerides
Follicle stimulating hormone (females only, to confirm 
WCBP)eGFR
Endocrine
C-peptide Additional lipids
HDL cholesterol
Pancreas (Exocrine) LDL cholesterol
Pancreatic amylase
Lipase Hemoglobin A1c
Free Fatty Acid
Hepatitis B
Hepatitis B Core Antibody
Hepatitis B Surface Antigen
Hepatitis B Surface Antibody
Drug concentratio n
LY3209590
Immunogenicity
Anti-LY3209590 Pharmacogenetic sample
Non-pharmacogenetic samples
I8H-MC-BDCM Clinical Protocol Page 71
LY3209590Abbreviations:  HDL = high density lipoprotein; LDL = low density lipoprotein; RBC = red blood cells ;
WBC = white blood cells ; WCBP = women of child bearing potential .
aResults will be confirmed by the Central Lab at the time of initial testing .
bRefer to the Schedule of Activities .
cAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted.
dUrine pregnancy tests (analyzed on -site) to be performed at Visits 3, 801, and ET and serum pregnancy test 
(analy zed by  central laborato ry) to be performed at Visit 1 for women of childbearing potential.  Additional 
pregnancy tests may be performed at the investigator’s discretion during the study .
I8H-MC-BDCM Clinical Protocol Page 72
LY3209590Appendix 3. Study  Governance Considerations
I8H-MC-BDCM Clinical Protocol Page 73
LY3209590Appendix 3.1.Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 3.1.1 .Informed Consent
The invest igator is responsible for:
Ensuring that the study  participant /study  parti cipant ’s legal representative 
understands the nature of the study , the potenti al risks and benefi ts of 
participat ing in the study , and that thei r parti cipation is vo luntary.
Ensuring that informed consent is given by each study  parti cipant /study  
participant ’s legal representative .  This includes obtaining the appropriate 
signatures and dates on the informed consent form  (ICF) prior to the 
perform ance of any protocol  procedures and prior to the administration of 
investigat ional product.
Answering any quest ions the study  parti cipant /study participant ’s legal 
representative may have throughout the study  and sha ring in a t imely manner 
any new information that may  be relevant to the study participant /study  
participant ’s legal representative ’s willingness to continue his or her 
participat ion in the study.
Ensuring that a copy  of the ICF is provi ded to the parti cipant or the 
participant’s l egal representative and is kept on file.
Ensuring that the m edical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the 
date the written consent was obtaine d. The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
A legal representative must give informed consent for a child to participate in this study.  In 
addition to inform ed consent given by the legal representative, the child may  be required to give 
docum ented assent, if capable.
Appendix 3.1.2 .Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for study participant s.  
Individual investigators may have addit ional local requirements or processes.
Invest igator(s) will be responsible for subject recruit ment through local requirements or 
processes.  
Appendix 3.1. 3.Ethical Review
The invest igator or an appropriate local representative must give assurance that the ethical 
review board (ERB) was properly  consti tuted and convened as required by Internat ional Council
for Harm onisat ion (ICH) guidelines and other applicable laws and regulati ons.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
I8H-MC-BDCM Clinical Protocol Page 74
LY3209590including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
theprotocol and related amendments and addenda
current Invest igator B rochure ( IB)
inform ed consent form  
other relevant docum ents ( for example , curri cula vi tae, adverti sements)
Appendix 3.1. 4.Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with the:
consensus ethics principles de rived from  internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations
Some ofthe obligat ions of the sponsor will be assigned to a third party .
Appendix 3.1 .5.Investigator Information
Physicians with a specialt y in diabetes will participate as invest igators in this clinical trial.
Physicians with a specialt y in diabetes working in teaching or nonteaching hospitals or out study 
participant setting will participate as invest igators in this clinical trial.
Appendix 3.1. 6.Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the be st 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly represent ative.
Appendix 3.1. 7.Final Report Signature
The invest igator will sign the final clinical study report (CSR) for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The CSR coordinat ing invest igator will sign the f inal CSR for this study , indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .
I8H-MC-BDCM Clinical Protocol Page 75
LY3209590The invest igator with the most analyzable study  parti cipant swill serve as the CSR coordinat ing 
investigator.  If this investigator is unable to fulfill this function, another invest igator will be 
chosen by Lilly to serve as the CSR coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the CRFs, and 
study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the study  parti cipant
data recorded against source documents at the study site.  The study  may be audi ted by Lilly or 
its representati ves, and/or regulatory  agencies at any  time.  Invest igators will be given notice 
before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requeste d, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor. 
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of the eCRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF .
Addit ionally , clinical  outcom e assessment (COA) data (questionnaires, scales, self -reported di ary 
data, rating scales, etc.) will be co llected by the study  parti cipant (invest igator site personnel), 
I8H-MC-BDCM Clinical Protocol Page 76
LY3209590via a paper source document and will be transcribed by  the invest igator site per sonnel into the 
EDC sy stem .
Data collected via the sponsor- provided data capture system(s) will be stored at third party .  The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem (s).  P rior to decommissioning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system, and electronic t ransfers will be provided to the invest igator 
for review and retent ion.  Data will subsequently be transferred fro m the central  vendor to the 
Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global produc t 
complaint m anagement sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory ,or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3. 4.Publication Policy
The publicat ion policy for Study  I8H-MC-BDCM is described in Clinical Trial Agreement .
I8H-MC-BDCM Clinical Protocol Page 77
LY3209590Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th study  parti cipant s in consultation wit h Lilly, or i ts desi gnee,
clinical research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I8H-MC-BDCM Clinical Protocol Page 78
LY3209590Appendix 5. Methods of Contraception
Highly Effective Methods of Contraception:
Combined oral contraceptive pill or mini pill
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena® and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total  abstinence
Vasectomy  for men in clinical trials
Partner wi th vasectomy for women in clinical trials
Essure
Combination of 2 effective methods of contraception 
Male condom wit h spermicide
Female condo m with spermicide
Diaphragm  with spermicide
Cervical sponge wit h condom
Cervical cap wit h spermicide
I8H-MC-BDCM Clinical Protocol Page 79
LY3209590Appendix 6. New York Hea rt Association Cardiac Disease 
Classification
Current classificat ion can be found at 
https://m anual.j ointcommissio n.org/rel eases/TJC2016A/DataElem0439.ht ml
I8H-MC-BDCM Clinical Protocol Page 80
LY3209590Appendix 7. Dosing Guidance 
LY3209590 will be init iated at a loading dose  estimated to 
be co mparable to the total daily basal insulin dose already administered prior to randomizat ion.  
The  dose are shown in Table BDCM.5 .  New 
dosing algorithm sdevel oped specifically  for LY3209590 will be used by  investi gators for 
adjusting fast ing glucose to achieve glycemic goals (Table BDCM.6 ).  In si tuations where study  
participant safet y is a concern or where dose adjustments have not had the desired therapeutic 
effect, invest igators may only make adjust ments to the dose of LY3209590 recommended by the 
dose-adjust ment algorithm after consul tation wi th Lilly.   
At the time of site visit or telephone visit, the investigator will assess the study  parti cipant’s 
glycemic control for the previous week and, if necessary, inform the study part icipant about any  
needed dose adjustment.  The dose will be based on the study participant’s blood glucose value.  
Adherence to the dosing algorithm provided for this study  is requi red from Visi t 3 
(randomization) up to Visit 21 (Week 32, inclusive) and will be mo nitored peri odically  by the 
study  team .  Dose increases may be made no sooner than (algorithm #1) or (algorithm 
#2)  following the l ast dose increase.  There should be no dose increase or decrease if at 
least , respectively, have not elapsed since the previous dose increase.  Any 
deviat ions from this gui dance m ust be approved by Lilly .
LY3209590 dose increase algorithm will be determined based on the mean of the FBG 
(determined from self -monitoring of blood glucose [SMBG]) .  Due to the l ong 
half-life of LY3209590, the change i n fasting glucose response fo llowing dose adj ustment may  
take several weeks to reach new level; therefore, less frequent dose adjust ment is recommended 
to minimize prolonged variat ion in glycemic control.    
The insulin dose may not be increased if  
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I8H-MC-BDCM Clinical Protocol Page 81
LY3209590Table BDCM .5 LY3209590 Loading Dose 
CCI
I8H-MC-BDCM Clinical Protocol Page 82
LY3209590Table BDCM .6 LY3209590 Titration Algorithm 
CCI
Leo Document ID = 918a14c6-c102-4f81-94a2-a4675ac3c540
Approver: )
Approval Date & Time: 31-Aug-2018 14:54:01 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 31-Aug-2018 16:06:36 GMT
Signature meaning: Approved
PPD
PPD